Does Periodontal Health Improve Glycemic Control?

Article Type
Changed
Display Headline
Does Periodontal Health Improve Glycemic Control?

Article PDF
Author and Disclosure Information

Issue
Federal Practitioner - 27(6)
Publications
Page Number
E1
Legacy Keywords
periodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolismperiodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolism
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Issue
Federal Practitioner - 27(6)
Issue
Federal Practitioner - 27(6)
Page Number
E1
Page Number
E1
Publications
Publications
Article Type
Display Headline
Does Periodontal Health Improve Glycemic Control?
Display Headline
Does Periodontal Health Improve Glycemic Control?
Legacy Keywords
periodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolismperiodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolism
Legacy Keywords
periodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolismperiodontal, glycemic, glycemic control, diabetes, periodontal health, periodontitis, A1c, fasting plasma glucose, glucose metabolism
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Grand Rounds: Woman, 80, With Hallucinations and Tremors

Article Type
Changed
Display Headline
Woman, 80, With Hallucinations and Tremors

An 80-year-old Mandarin-speaking Chinese woman was referred to a mental health outpatient clinic for evaluation and treatment. The patient had a history of mild depression, for which she had been treated for many years with sertraline.

Five years earlier at age 75, the patient had been evaluated by a psychiatrist after she began to experience psychotic symptoms, including frequent repetitive auditory hallucinations of people counting, alternating with music from her childhood. At that time, she also had persecutory paranoid thoughts and delusional thinking that she was receiving messages in Mandarin while watching American TV programs. Initially, her only cognitive disturbance was an inability to differentiate among numbers on a calendar or a telephone keypad. No reports of memory problems were noted. Although the patient acknowledged auditory hallucinations, she denied experiencing command auditory hallucinations or hallucinations of other forms. The patient had no history of suicide attempts and denied suicidal or homicidal ideation. She had no history of psychiatric hospitalization.

The psychiatrist made a diagnosis of major depressive disorder with psychotic features, not otherwise specified1 and prescribed sertraline 50 mg/d. The patient was also started on risperidone 0.25 mg/d for management of her psychotic symptoms, with the dosage gradually increased to 2.0 mg/d over five years. While taking this combination, the patient experienced stable mood and fewer paranoid thoughts, although her auditory hallucinations continued.

Two months before the current visit, the patient moved into a retirement living facility, and she reported having adapted well to the new setting. She was sleeping well and had a good appetite. Her BMI was within normal range.

The patient described herself as a single parent for nearly 40 years, raising one daughter. Formerly high functioning, she had held a full-time clerical job until age 70. She appeared well-groomed, polite but anxious, and oriented to time, person, and place. Her speech was normal, her thought processes were coherent, and her mood was stable. However, her affect was constricted; she acknowledged auditory hallucinations, which impaired her thought content. The patient reported feeling increased anxiety prior to any nonroutine activity, such as a doctor’s appointment; this, she said, would cause insomnia, leaving her to pace in her room.

During the examination, fine tremors on upper and lower extremities were noted. The patient’s Abnormal Involuntary Movement Scale (AIMS) score2 was 13, which placed her in the highest risk category for antipsychotic-induced dopamine-blockade extrapyramidal symptoms (EPS). The patient was found to be negative for tardive dyskinesia, with no abnormal facial movements. She was aware of the tremors in her limbs and said she felt bothered by them.

The patient had an unsteady gait and used a four-point walker. Her Mini-Mental State Exam (MMSE) score3 was 28/30, which was normal for her age and education level (high school completed).

Apart from the described symptoms, the patient was healthy for her age and had no other medical diagnosis. Her vital signs were within normal range. The medical work-up to rule out other causes of dementia yielded negative results. Lab values were normal, including electrolyte levels and thyroid tests. The patient’s hearing test showed age-related hearing loss of full range, not limited to high pitch. She was able to engage in a meaningful conversation at a normal volume. Clinically, however, it was concerning to observe the possible signs of EPS and the relatively high risperidone dosage, considering the patient’s advanced age.

After the meeting with the patient, a treatment plan was created to 1) gradually reduce the dosage of antipsychotic medication, and 2) refer her to a neurologist for a complete work-up to rule out underlying neurologic disorders, such as dementia. Risperidone was tapered by increments of 0.25 mg/d every three to four weeks; throughout this process, the patient was closely monitored by the nursing staff at the retirement living facility. Monthly appointments were scheduled at the outpatient mental health clinic for evaluation and medication management.

Two months after the initial mental health clinic visit, the patient’s condition was pronounced stable on the current regimen of sertraline 50 mg/d and risperidone 1.0 mg/d. She was later seen by a neurologist, who made a diagnosis of Parkinson’s disease and placed her on carbidopa-­levodopa (1 1/2 tablets, 25/100 mg, tid). The patient’s auditory hallucinations continued with the same intensity as at baseline, but fewer tremors were noted in her extremities. By six months into the tapering process (with risperidone reduced at that time to 0.25 mg/d and carbidopa-levodopa to 25/100 mg tid), the patient had begun to experience dissipation of the tremors, and her AIMS score2 was 0. She was able to replace her four-point walker with a cane.

 

 

One year after her initial visit to the mental health clinic, the patient’s neurologist suggested replacing risperidone with quetia­pine (12.5 mg/d) for its improved tolerability and lower adverse effect profile.4 She continued to take sertraline and carbidopa-levodopa.

Improvement of symptoms was noted following the switch. After one month on the revised regimen, the patient reported that the number of auditory hallucinations persisted, but that their intensity had decreased dramatically. She had a brighter affect and appeared to feel uplifted and more energetic. She became involved in the social activities offered at the retirement living facility and the mental health clinic. She also maintained a steady gait without her cane. According to the patient’s daughter, her mother was at her best psychological state since the onset of psychotic symptoms six years earlier. The pharmacologic regimen had reached its maximum benefit.

At a mental health appointment at the outpatient clinic 18 months after her initial visit there, it was evident that the patient’s auditory hallucinations persisted as a major stressor. She began to complain about other residents in her facility. She said she disliked the resident with whom she shared meals, and she claimed that other residents often spit on the floor in front of her room. The nursing staff did not confirm these incidents, which they considered a delusion despite the patient’s “evidence” (the tissues she said she had used to clean up).

Additionally, a new theme had emerged in the patient’s auditory hallucinations. She reported hearing a male voice that announced changes in meal times. Although she knew there was no public address system in her room or in the hallway, the “announcement” was so convincing that she would go to the dining room and once there, realize that nothing had changed. She seemed to drift between reality and her hallucinations/delusions. According to her daughter, the patient’s independent and reserved personality forced her to internalize her stressors—in this case, her frustration about the other residents—which fed into her hallucinations and delusions.

In response to her worsening psychotic symptoms, the patient’s provider increased her quetia­pine dosage from 12.5 mg/d to 25 mg/d. Her MMSE score3 at this visit was 25/30.

Two months later, the patient exhibited increasing symptoms of paranoia, delusions, and auditory hallucinations. She continued to respond to the “broadcast” messages about meal times, and she voiced her frustrations to others who spoke Mandarin. She became agitated in response to out-of-the-ordinary events. When her alarm clock battery ran out, for example, she insisted that “a man’s voice” kept reminding her to replace the battery; in response, she placed the alarm clock in the refrigerator, later explaining, “Now I don’t need to worry about it.”

Her cognitive status began to show obvious, progressive deterioration, with an MMSE score3 of 22/30 at this visit—a significant reduction from previous scores. Worsening of her short-term memory became apparent when she had difficulty playing bingo and was unable to remember her appointment or the current date. She became upset when others corrected her.

In a review of the trends in this patient’s clinical presentation, it became increasingly evident to the patient’s mental health care providers that she had Lewy body dementia.

DISCUSSION
Dementia with Lewy bodies (DLB), a progressive disease, is the second most common cause of neurodegenerative dementia after Alzheimer’s disease.5-7 It is estimated that DLB accounts for 20% of US cases of dementia (ie, about 800,000 patients).8,9 Although public awareness of DLB is on the rise, the disorder is still underrecognized and underdiagnosed because its clinical manifestations so closely resemble those of Alzheimer’s disease, Parkinson’s disease, and psychosis.10,11

Clinical symptoms of DLB include progressive cognitive decline, cognitive fluctuation, EPS, and parkinsonism; hallucinations involving all five senses, particularly sight; delusions; REM sleep disturbance, with or without vivid and frightening dreams; changes in mood and behavior; impaired judgment and insight; and autonomic dysfunction, such as orthostatic hypotension and carotid-sinus hypersensitivity.5,11-15

The symptoms of DLB are caused by the accumulations of Lewy bodies, that is, deposits of alpha-synuclein protein in the nuclei of neurons. Lewy bodies destroy neurons over time, resulting in the destruction of dopaminergic and acetylcholinergic pathways from the brain stem to areas of the cerebral cortex associated with cognition and motor functions.4,5,16

DLB is a spectrum disorder; it often coexists with Parkinson’s disease or Alzheimer’s disease, as Lewy bodies are also found in patients with these illnesses.7 This poses a challenge for formulating a differential diagnosis, particularly in patients with fluctuating cognition,10 and for attempting to establish disease prevalence.

Diagnosis
Currently, a conclusive diagnosis of DLB can be confirmed only through postmortem autopsy, although use of medial temporal lobe volume (via structural MRI) and regional blood flow (via single photon emission CT [SPECT] tracers) is being investigated.17

 

 

The diagnosis of DLB is currently based on the presenting clinical symptoms and the exclusion of other medical conditions whose symptoms mimic those of DLB.7 The screening assessment may include a neurologic/psychiatric assessment (MMSE, psychiatric evaluation, and interviews with family members or caretakers), neuroimaging such as MRI to rule out other organic causes, and laboratory evaluation to rule out potentially reversible causes of dementia, including electrolyte imbalance, vitamin deficiency (specifically vitamin B12), anemia, thyroid dysfunction, and kidney or liver impairment.18

The American Psychiatric Assocation1 categorizes DLB under “Dementia Due to Other General Medical Conditions” (294.1x). The World Health Organization19 includes it among “Other specified degenerative diseases of the nervous system” (G31.8).

Treatment
Lewy body dementia is an irreversible neurologic degenerative disorder. Treatment for DLB comprises symptom management, primarily through pharmacology; however, the response to medication is highly individualized. Treatment includes management of the following symptoms:

Cognitive impairment. Cholinesterase inhibitors, such as rivastigmine (3 to 12 mg/d), donepezil (10 mg/d), or galantamine (titrated up to 12 mg bid),20-23 improve attention and behavior and reduce apathy, anxiety, delusions, and hallucinations. As cognitive impairment worsens, memantine (10 mg bid) may be effective.24 The potential for anticholinergic adverse effects requires close monitoring in patients taking these agents.

Parkinsonian symptoms. Medications indicated for Parkinson’s disease and syndrome, such as carbidopa-levodopa (25/100 mg tid), can be effective; dosage may be slowly titrated upward as tolerated and if needed for symptom management.25,26 The dopaminergic effect of antiparkinson medications may intensify the psychotic symptoms and worsen the REM sleep pattern. In this case, a low-dose atypical antipsychotic is suggested27,28 (see below).

Psychotic symptoms. An atypical antipsychotic agent, such as quetiapine (12.5 mg), risperidone (0.25 mg), olanzapine (2.5 mg), ziprasidone (20 mg), aripiprazole (2 mg), or paliperidone (1.5 mg), may be used. Because of the DLB-associated risk of neuroleptic sensitivity, atypical antipsychotic agents should be initiated at a low dose with slow upward titration17,26,29; quetiapine appears less likely than risperidone or olanzapine to cause neuroleptic sensitivity or to trigger EPS.4 For Asian patients, who often respond to lower doses of these medications (and are more easily affected by associated adverse effects), Chen et al30 recommend a starting dose of about one-half the recommended dose.

Depression. An SSRI antidepressant with relatively simple pharmacologic properties and moderate half-life may be used to manage symptoms of depression.26,31,32 Long–half-life SSRIs (eg, fluoxetine) should be avoided in elderly patients; in response to SNRIs (serotonin-norepinephrine reuptake inhibitors), these patients may experience elevated blood pressures and pulses, with subsequent morbidity.33

REM sleep disturbances. Clo­nazepam (0.25 mg), melatonin (3.0 mg), or quetiapine (12.5 mg) may be administered at bedtime.34

Important Lessons
In general, providers should consider the benefits and risks of any pharmacologic treatment and avoid polypharmacy, if possible. Family and caretakers should be included in the treatment planning, with a focus on prioritizing and managing the most debilitating symptoms or dysfunctions that prompt concerns for safety.

For optimal homeostasis, some DLB patients may require joint pharmacologic modalities that appear counterintuitive—for example, an antiparkinsonism (dopaminergic) agent for parkinsonian symptoms or neuroleptic-induced EPS, versus an antipsychotic (eg, a dopamine antagonist) to treat profound hallucinations.26

As the response to treatment for DLB is highly individualized, it is essential to titrate and augment with care.

CONCLUSION
In DLB, as with other dementing illnesses, the onset of symptoms can be gradual and insidious, posing a great challenge to the clinician who seeks to confirm the diagnosis. In the illness’s early stages, the clinician may have to treat targeted symptoms and adjust the treatment plan once signs of the pathologic origins emerge.

It is critical to understand the mechanisms of psychotropic medications and targeted neurotransmitters when evaluating treatment for DLB. Titrating or augmenting these medications in elderly patients requires the clinician to follow a principle of start low and go slow, making only one change at a time.

It is always helpful to include family members in the patient’s care and to gather information on previous history, personality traits, family history, and cultural components. It is also important to communicate with other specialists to implement collaborative care.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text revision). Washington, DC: American Psychiatric Association; 2000:167.

2. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). www.atlantapsychia try.com/forms/AIMS.pdf. Accessed May 20, 2010.

3. Mini–Mental State Examination. www.nmaging .state.nm.us/pdf_files/Mini_Mental_Status_Exam.pdf. Accessed May 20, 2010.

4. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 suppl 11:16-22.

5. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007;27(1):42-47.

6. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 suppl):417-423.

7. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47(5):1113-1124.

8. Hill C, Reiss N. Lewy body dementia (2008). www.mentalhelp.net/poc/view_doc.php?type=doc& id=13151&cn=231. Accessed May 20, 2010.

9. Lewy Body Dementia Association, Inc. Lewy body dementia: current issues in diagnosis and treatment. www.lewybodydementia.org. Accessed May 20, 2010.

10. Varanese S, Perfetti B, Monaco D, et al. Fluctuating cognition and different cognitive and behavioural profiles in Parkinson’s disease with dementia: comparison of dementia with Lewy bodies and Alzheimer’s disease. J Neurol. 2010 Jan 22. [Epub ahead of print]

11. Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disorder. 2010;25(2):167-171.

12. Gagnon JF, Postuma RB, Mazza S, et al. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5(5):424-432.

13. Dodel R, Csoti I, Ebersbach G, et al. Lewy body dementia and Parkinson’s disease with dementia. J Neurol. 2008;255 suppl 5:39-47.

14. Sonnesyn H, Nilsen DW, Rongve A, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307-313.

15. Kenny RA, Shaw FE, O’Brien JT, et al. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry. 2004;75(7):966-971.

16. Hickey C, Chisholm T, Passmore MJ, et al. Differentiating the dementias: revisiting synucleinopathies and tauopathies. Curr Alzheimer Res. 2008;5(1):52-60.

17. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry. 2003; 8(1):46-57.

18. Bird TD, Miller BL. Dementia. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical; 2008:2536-2549.

19. World Health Organization. International Classification of Diseases (ICD), Version 2007. Chapter VI: Diseases of the Central Nervous System. http://apps.who.int/classifications/apps/icd/icd10online/index.htm?kg00.htm+. Accessed May 20, 2010.

20. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036.

21. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s disease and Alzheimer’s disease: similarities and differences. J Alzheimers Dis. 2007;11(4):509-519.

22. Lam B, Hollingdrake E, Kennedy JL, et al. Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics. 2009;4(2):91-106.

23. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;(3):CD003672.

24. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618.

25. Merck & Co., Inc. Sinemet® CR (carbidopa-levodopa) sustained-release tablets. http://packageinserts.bms.com/pi/pi_sinemet_cr.pdf. Accessed May 20, 2010.

26. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027-2037.

27. Kato K, Wada T, Kawakatsu S, Otani K. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):201-203.

28. Yamauchi K, Takehisa M, Tsuno M, et al. Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. Gen Hosp Psychiatry. 2003;25(2):140-142.

29. Stahl SM. The Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge University Press; 2006:459.

30. Chen JP, Barron C, Lin KM, Chung H. Prescribing medication for Asians with mental disorders. West J Med. 2002;176(4):271-275.

31. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.

32. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465.

33. Schwab W, Messinger-Rapport B, Franco K. Psychiatric symptoms of dementia: treatable, but no silver bullet. Cleve Clin J Med. 2009;76(3):167-174.

34. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742-747

Author and Disclosure Information

 

Hsin-Yi (Jean) Tang, PhD, ARNP, PMHNP, Karen S. Feldt, PhD, ARNP, GNP, Deonne J. Brown-Benedict, DNP, ARNP, FNP

Issue
Clinician Reviews - 20(6)
Publications
Topics
Page Number
13-17
Legacy Keywords
Lewy body, dementia, hallucinations, tremorsLewy body, dementia, hallucinations, tremors
Sections
Author and Disclosure Information

 

Hsin-Yi (Jean) Tang, PhD, ARNP, PMHNP, Karen S. Feldt, PhD, ARNP, GNP, Deonne J. Brown-Benedict, DNP, ARNP, FNP

Author and Disclosure Information

 

Hsin-Yi (Jean) Tang, PhD, ARNP, PMHNP, Karen S. Feldt, PhD, ARNP, GNP, Deonne J. Brown-Benedict, DNP, ARNP, FNP

An 80-year-old Mandarin-speaking Chinese woman was referred to a mental health outpatient clinic for evaluation and treatment. The patient had a history of mild depression, for which she had been treated for many years with sertraline.

Five years earlier at age 75, the patient had been evaluated by a psychiatrist after she began to experience psychotic symptoms, including frequent repetitive auditory hallucinations of people counting, alternating with music from her childhood. At that time, she also had persecutory paranoid thoughts and delusional thinking that she was receiving messages in Mandarin while watching American TV programs. Initially, her only cognitive disturbance was an inability to differentiate among numbers on a calendar or a telephone keypad. No reports of memory problems were noted. Although the patient acknowledged auditory hallucinations, she denied experiencing command auditory hallucinations or hallucinations of other forms. The patient had no history of suicide attempts and denied suicidal or homicidal ideation. She had no history of psychiatric hospitalization.

The psychiatrist made a diagnosis of major depressive disorder with psychotic features, not otherwise specified1 and prescribed sertraline 50 mg/d. The patient was also started on risperidone 0.25 mg/d for management of her psychotic symptoms, with the dosage gradually increased to 2.0 mg/d over five years. While taking this combination, the patient experienced stable mood and fewer paranoid thoughts, although her auditory hallucinations continued.

Two months before the current visit, the patient moved into a retirement living facility, and she reported having adapted well to the new setting. She was sleeping well and had a good appetite. Her BMI was within normal range.

The patient described herself as a single parent for nearly 40 years, raising one daughter. Formerly high functioning, she had held a full-time clerical job until age 70. She appeared well-groomed, polite but anxious, and oriented to time, person, and place. Her speech was normal, her thought processes were coherent, and her mood was stable. However, her affect was constricted; she acknowledged auditory hallucinations, which impaired her thought content. The patient reported feeling increased anxiety prior to any nonroutine activity, such as a doctor’s appointment; this, she said, would cause insomnia, leaving her to pace in her room.

During the examination, fine tremors on upper and lower extremities were noted. The patient’s Abnormal Involuntary Movement Scale (AIMS) score2 was 13, which placed her in the highest risk category for antipsychotic-induced dopamine-blockade extrapyramidal symptoms (EPS). The patient was found to be negative for tardive dyskinesia, with no abnormal facial movements. She was aware of the tremors in her limbs and said she felt bothered by them.

The patient had an unsteady gait and used a four-point walker. Her Mini-Mental State Exam (MMSE) score3 was 28/30, which was normal for her age and education level (high school completed).

Apart from the described symptoms, the patient was healthy for her age and had no other medical diagnosis. Her vital signs were within normal range. The medical work-up to rule out other causes of dementia yielded negative results. Lab values were normal, including electrolyte levels and thyroid tests. The patient’s hearing test showed age-related hearing loss of full range, not limited to high pitch. She was able to engage in a meaningful conversation at a normal volume. Clinically, however, it was concerning to observe the possible signs of EPS and the relatively high risperidone dosage, considering the patient’s advanced age.

After the meeting with the patient, a treatment plan was created to 1) gradually reduce the dosage of antipsychotic medication, and 2) refer her to a neurologist for a complete work-up to rule out underlying neurologic disorders, such as dementia. Risperidone was tapered by increments of 0.25 mg/d every three to four weeks; throughout this process, the patient was closely monitored by the nursing staff at the retirement living facility. Monthly appointments were scheduled at the outpatient mental health clinic for evaluation and medication management.

Two months after the initial mental health clinic visit, the patient’s condition was pronounced stable on the current regimen of sertraline 50 mg/d and risperidone 1.0 mg/d. She was later seen by a neurologist, who made a diagnosis of Parkinson’s disease and placed her on carbidopa-­levodopa (1 1/2 tablets, 25/100 mg, tid). The patient’s auditory hallucinations continued with the same intensity as at baseline, but fewer tremors were noted in her extremities. By six months into the tapering process (with risperidone reduced at that time to 0.25 mg/d and carbidopa-levodopa to 25/100 mg tid), the patient had begun to experience dissipation of the tremors, and her AIMS score2 was 0. She was able to replace her four-point walker with a cane.

 

 

One year after her initial visit to the mental health clinic, the patient’s neurologist suggested replacing risperidone with quetia­pine (12.5 mg/d) for its improved tolerability and lower adverse effect profile.4 She continued to take sertraline and carbidopa-levodopa.

Improvement of symptoms was noted following the switch. After one month on the revised regimen, the patient reported that the number of auditory hallucinations persisted, but that their intensity had decreased dramatically. She had a brighter affect and appeared to feel uplifted and more energetic. She became involved in the social activities offered at the retirement living facility and the mental health clinic. She also maintained a steady gait without her cane. According to the patient’s daughter, her mother was at her best psychological state since the onset of psychotic symptoms six years earlier. The pharmacologic regimen had reached its maximum benefit.

At a mental health appointment at the outpatient clinic 18 months after her initial visit there, it was evident that the patient’s auditory hallucinations persisted as a major stressor. She began to complain about other residents in her facility. She said she disliked the resident with whom she shared meals, and she claimed that other residents often spit on the floor in front of her room. The nursing staff did not confirm these incidents, which they considered a delusion despite the patient’s “evidence” (the tissues she said she had used to clean up).

Additionally, a new theme had emerged in the patient’s auditory hallucinations. She reported hearing a male voice that announced changes in meal times. Although she knew there was no public address system in her room or in the hallway, the “announcement” was so convincing that she would go to the dining room and once there, realize that nothing had changed. She seemed to drift between reality and her hallucinations/delusions. According to her daughter, the patient’s independent and reserved personality forced her to internalize her stressors—in this case, her frustration about the other residents—which fed into her hallucinations and delusions.

In response to her worsening psychotic symptoms, the patient’s provider increased her quetia­pine dosage from 12.5 mg/d to 25 mg/d. Her MMSE score3 at this visit was 25/30.

Two months later, the patient exhibited increasing symptoms of paranoia, delusions, and auditory hallucinations. She continued to respond to the “broadcast” messages about meal times, and she voiced her frustrations to others who spoke Mandarin. She became agitated in response to out-of-the-ordinary events. When her alarm clock battery ran out, for example, she insisted that “a man’s voice” kept reminding her to replace the battery; in response, she placed the alarm clock in the refrigerator, later explaining, “Now I don’t need to worry about it.”

Her cognitive status began to show obvious, progressive deterioration, with an MMSE score3 of 22/30 at this visit—a significant reduction from previous scores. Worsening of her short-term memory became apparent when she had difficulty playing bingo and was unable to remember her appointment or the current date. She became upset when others corrected her.

In a review of the trends in this patient’s clinical presentation, it became increasingly evident to the patient’s mental health care providers that she had Lewy body dementia.

DISCUSSION
Dementia with Lewy bodies (DLB), a progressive disease, is the second most common cause of neurodegenerative dementia after Alzheimer’s disease.5-7 It is estimated that DLB accounts for 20% of US cases of dementia (ie, about 800,000 patients).8,9 Although public awareness of DLB is on the rise, the disorder is still underrecognized and underdiagnosed because its clinical manifestations so closely resemble those of Alzheimer’s disease, Parkinson’s disease, and psychosis.10,11

Clinical symptoms of DLB include progressive cognitive decline, cognitive fluctuation, EPS, and parkinsonism; hallucinations involving all five senses, particularly sight; delusions; REM sleep disturbance, with or without vivid and frightening dreams; changes in mood and behavior; impaired judgment and insight; and autonomic dysfunction, such as orthostatic hypotension and carotid-sinus hypersensitivity.5,11-15

The symptoms of DLB are caused by the accumulations of Lewy bodies, that is, deposits of alpha-synuclein protein in the nuclei of neurons. Lewy bodies destroy neurons over time, resulting in the destruction of dopaminergic and acetylcholinergic pathways from the brain stem to areas of the cerebral cortex associated with cognition and motor functions.4,5,16

DLB is a spectrum disorder; it often coexists with Parkinson’s disease or Alzheimer’s disease, as Lewy bodies are also found in patients with these illnesses.7 This poses a challenge for formulating a differential diagnosis, particularly in patients with fluctuating cognition,10 and for attempting to establish disease prevalence.

Diagnosis
Currently, a conclusive diagnosis of DLB can be confirmed only through postmortem autopsy, although use of medial temporal lobe volume (via structural MRI) and regional blood flow (via single photon emission CT [SPECT] tracers) is being investigated.17

 

 

The diagnosis of DLB is currently based on the presenting clinical symptoms and the exclusion of other medical conditions whose symptoms mimic those of DLB.7 The screening assessment may include a neurologic/psychiatric assessment (MMSE, psychiatric evaluation, and interviews with family members or caretakers), neuroimaging such as MRI to rule out other organic causes, and laboratory evaluation to rule out potentially reversible causes of dementia, including electrolyte imbalance, vitamin deficiency (specifically vitamin B12), anemia, thyroid dysfunction, and kidney or liver impairment.18

The American Psychiatric Assocation1 categorizes DLB under “Dementia Due to Other General Medical Conditions” (294.1x). The World Health Organization19 includes it among “Other specified degenerative diseases of the nervous system” (G31.8).

Treatment
Lewy body dementia is an irreversible neurologic degenerative disorder. Treatment for DLB comprises symptom management, primarily through pharmacology; however, the response to medication is highly individualized. Treatment includes management of the following symptoms:

Cognitive impairment. Cholinesterase inhibitors, such as rivastigmine (3 to 12 mg/d), donepezil (10 mg/d), or galantamine (titrated up to 12 mg bid),20-23 improve attention and behavior and reduce apathy, anxiety, delusions, and hallucinations. As cognitive impairment worsens, memantine (10 mg bid) may be effective.24 The potential for anticholinergic adverse effects requires close monitoring in patients taking these agents.

Parkinsonian symptoms. Medications indicated for Parkinson’s disease and syndrome, such as carbidopa-levodopa (25/100 mg tid), can be effective; dosage may be slowly titrated upward as tolerated and if needed for symptom management.25,26 The dopaminergic effect of antiparkinson medications may intensify the psychotic symptoms and worsen the REM sleep pattern. In this case, a low-dose atypical antipsychotic is suggested27,28 (see below).

Psychotic symptoms. An atypical antipsychotic agent, such as quetiapine (12.5 mg), risperidone (0.25 mg), olanzapine (2.5 mg), ziprasidone (20 mg), aripiprazole (2 mg), or paliperidone (1.5 mg), may be used. Because of the DLB-associated risk of neuroleptic sensitivity, atypical antipsychotic agents should be initiated at a low dose with slow upward titration17,26,29; quetiapine appears less likely than risperidone or olanzapine to cause neuroleptic sensitivity or to trigger EPS.4 For Asian patients, who often respond to lower doses of these medications (and are more easily affected by associated adverse effects), Chen et al30 recommend a starting dose of about one-half the recommended dose.

Depression. An SSRI antidepressant with relatively simple pharmacologic properties and moderate half-life may be used to manage symptoms of depression.26,31,32 Long–half-life SSRIs (eg, fluoxetine) should be avoided in elderly patients; in response to SNRIs (serotonin-norepinephrine reuptake inhibitors), these patients may experience elevated blood pressures and pulses, with subsequent morbidity.33

REM sleep disturbances. Clo­nazepam (0.25 mg), melatonin (3.0 mg), or quetiapine (12.5 mg) may be administered at bedtime.34

Important Lessons
In general, providers should consider the benefits and risks of any pharmacologic treatment and avoid polypharmacy, if possible. Family and caretakers should be included in the treatment planning, with a focus on prioritizing and managing the most debilitating symptoms or dysfunctions that prompt concerns for safety.

For optimal homeostasis, some DLB patients may require joint pharmacologic modalities that appear counterintuitive—for example, an antiparkinsonism (dopaminergic) agent for parkinsonian symptoms or neuroleptic-induced EPS, versus an antipsychotic (eg, a dopamine antagonist) to treat profound hallucinations.26

As the response to treatment for DLB is highly individualized, it is essential to titrate and augment with care.

CONCLUSION
In DLB, as with other dementing illnesses, the onset of symptoms can be gradual and insidious, posing a great challenge to the clinician who seeks to confirm the diagnosis. In the illness’s early stages, the clinician may have to treat targeted symptoms and adjust the treatment plan once signs of the pathologic origins emerge.

It is critical to understand the mechanisms of psychotropic medications and targeted neurotransmitters when evaluating treatment for DLB. Titrating or augmenting these medications in elderly patients requires the clinician to follow a principle of start low and go slow, making only one change at a time.

It is always helpful to include family members in the patient’s care and to gather information on previous history, personality traits, family history, and cultural components. It is also important to communicate with other specialists to implement collaborative care.

An 80-year-old Mandarin-speaking Chinese woman was referred to a mental health outpatient clinic for evaluation and treatment. The patient had a history of mild depression, for which she had been treated for many years with sertraline.

Five years earlier at age 75, the patient had been evaluated by a psychiatrist after she began to experience psychotic symptoms, including frequent repetitive auditory hallucinations of people counting, alternating with music from her childhood. At that time, she also had persecutory paranoid thoughts and delusional thinking that she was receiving messages in Mandarin while watching American TV programs. Initially, her only cognitive disturbance was an inability to differentiate among numbers on a calendar or a telephone keypad. No reports of memory problems were noted. Although the patient acknowledged auditory hallucinations, she denied experiencing command auditory hallucinations or hallucinations of other forms. The patient had no history of suicide attempts and denied suicidal or homicidal ideation. She had no history of psychiatric hospitalization.

The psychiatrist made a diagnosis of major depressive disorder with psychotic features, not otherwise specified1 and prescribed sertraline 50 mg/d. The patient was also started on risperidone 0.25 mg/d for management of her psychotic symptoms, with the dosage gradually increased to 2.0 mg/d over five years. While taking this combination, the patient experienced stable mood and fewer paranoid thoughts, although her auditory hallucinations continued.

Two months before the current visit, the patient moved into a retirement living facility, and she reported having adapted well to the new setting. She was sleeping well and had a good appetite. Her BMI was within normal range.

The patient described herself as a single parent for nearly 40 years, raising one daughter. Formerly high functioning, she had held a full-time clerical job until age 70. She appeared well-groomed, polite but anxious, and oriented to time, person, and place. Her speech was normal, her thought processes were coherent, and her mood was stable. However, her affect was constricted; she acknowledged auditory hallucinations, which impaired her thought content. The patient reported feeling increased anxiety prior to any nonroutine activity, such as a doctor’s appointment; this, she said, would cause insomnia, leaving her to pace in her room.

During the examination, fine tremors on upper and lower extremities were noted. The patient’s Abnormal Involuntary Movement Scale (AIMS) score2 was 13, which placed her in the highest risk category for antipsychotic-induced dopamine-blockade extrapyramidal symptoms (EPS). The patient was found to be negative for tardive dyskinesia, with no abnormal facial movements. She was aware of the tremors in her limbs and said she felt bothered by them.

The patient had an unsteady gait and used a four-point walker. Her Mini-Mental State Exam (MMSE) score3 was 28/30, which was normal for her age and education level (high school completed).

Apart from the described symptoms, the patient was healthy for her age and had no other medical diagnosis. Her vital signs were within normal range. The medical work-up to rule out other causes of dementia yielded negative results. Lab values were normal, including electrolyte levels and thyroid tests. The patient’s hearing test showed age-related hearing loss of full range, not limited to high pitch. She was able to engage in a meaningful conversation at a normal volume. Clinically, however, it was concerning to observe the possible signs of EPS and the relatively high risperidone dosage, considering the patient’s advanced age.

After the meeting with the patient, a treatment plan was created to 1) gradually reduce the dosage of antipsychotic medication, and 2) refer her to a neurologist for a complete work-up to rule out underlying neurologic disorders, such as dementia. Risperidone was tapered by increments of 0.25 mg/d every three to four weeks; throughout this process, the patient was closely monitored by the nursing staff at the retirement living facility. Monthly appointments were scheduled at the outpatient mental health clinic for evaluation and medication management.

Two months after the initial mental health clinic visit, the patient’s condition was pronounced stable on the current regimen of sertraline 50 mg/d and risperidone 1.0 mg/d. She was later seen by a neurologist, who made a diagnosis of Parkinson’s disease and placed her on carbidopa-­levodopa (1 1/2 tablets, 25/100 mg, tid). The patient’s auditory hallucinations continued with the same intensity as at baseline, but fewer tremors were noted in her extremities. By six months into the tapering process (with risperidone reduced at that time to 0.25 mg/d and carbidopa-levodopa to 25/100 mg tid), the patient had begun to experience dissipation of the tremors, and her AIMS score2 was 0. She was able to replace her four-point walker with a cane.

 

 

One year after her initial visit to the mental health clinic, the patient’s neurologist suggested replacing risperidone with quetia­pine (12.5 mg/d) for its improved tolerability and lower adverse effect profile.4 She continued to take sertraline and carbidopa-levodopa.

Improvement of symptoms was noted following the switch. After one month on the revised regimen, the patient reported that the number of auditory hallucinations persisted, but that their intensity had decreased dramatically. She had a brighter affect and appeared to feel uplifted and more energetic. She became involved in the social activities offered at the retirement living facility and the mental health clinic. She also maintained a steady gait without her cane. According to the patient’s daughter, her mother was at her best psychological state since the onset of psychotic symptoms six years earlier. The pharmacologic regimen had reached its maximum benefit.

At a mental health appointment at the outpatient clinic 18 months after her initial visit there, it was evident that the patient’s auditory hallucinations persisted as a major stressor. She began to complain about other residents in her facility. She said she disliked the resident with whom she shared meals, and she claimed that other residents often spit on the floor in front of her room. The nursing staff did not confirm these incidents, which they considered a delusion despite the patient’s “evidence” (the tissues she said she had used to clean up).

Additionally, a new theme had emerged in the patient’s auditory hallucinations. She reported hearing a male voice that announced changes in meal times. Although she knew there was no public address system in her room or in the hallway, the “announcement” was so convincing that she would go to the dining room and once there, realize that nothing had changed. She seemed to drift between reality and her hallucinations/delusions. According to her daughter, the patient’s independent and reserved personality forced her to internalize her stressors—in this case, her frustration about the other residents—which fed into her hallucinations and delusions.

In response to her worsening psychotic symptoms, the patient’s provider increased her quetia­pine dosage from 12.5 mg/d to 25 mg/d. Her MMSE score3 at this visit was 25/30.

Two months later, the patient exhibited increasing symptoms of paranoia, delusions, and auditory hallucinations. She continued to respond to the “broadcast” messages about meal times, and she voiced her frustrations to others who spoke Mandarin. She became agitated in response to out-of-the-ordinary events. When her alarm clock battery ran out, for example, she insisted that “a man’s voice” kept reminding her to replace the battery; in response, she placed the alarm clock in the refrigerator, later explaining, “Now I don’t need to worry about it.”

Her cognitive status began to show obvious, progressive deterioration, with an MMSE score3 of 22/30 at this visit—a significant reduction from previous scores. Worsening of her short-term memory became apparent when she had difficulty playing bingo and was unable to remember her appointment or the current date. She became upset when others corrected her.

In a review of the trends in this patient’s clinical presentation, it became increasingly evident to the patient’s mental health care providers that she had Lewy body dementia.

DISCUSSION
Dementia with Lewy bodies (DLB), a progressive disease, is the second most common cause of neurodegenerative dementia after Alzheimer’s disease.5-7 It is estimated that DLB accounts for 20% of US cases of dementia (ie, about 800,000 patients).8,9 Although public awareness of DLB is on the rise, the disorder is still underrecognized and underdiagnosed because its clinical manifestations so closely resemble those of Alzheimer’s disease, Parkinson’s disease, and psychosis.10,11

Clinical symptoms of DLB include progressive cognitive decline, cognitive fluctuation, EPS, and parkinsonism; hallucinations involving all five senses, particularly sight; delusions; REM sleep disturbance, with or without vivid and frightening dreams; changes in mood and behavior; impaired judgment and insight; and autonomic dysfunction, such as orthostatic hypotension and carotid-sinus hypersensitivity.5,11-15

The symptoms of DLB are caused by the accumulations of Lewy bodies, that is, deposits of alpha-synuclein protein in the nuclei of neurons. Lewy bodies destroy neurons over time, resulting in the destruction of dopaminergic and acetylcholinergic pathways from the brain stem to areas of the cerebral cortex associated with cognition and motor functions.4,5,16

DLB is a spectrum disorder; it often coexists with Parkinson’s disease or Alzheimer’s disease, as Lewy bodies are also found in patients with these illnesses.7 This poses a challenge for formulating a differential diagnosis, particularly in patients with fluctuating cognition,10 and for attempting to establish disease prevalence.

Diagnosis
Currently, a conclusive diagnosis of DLB can be confirmed only through postmortem autopsy, although use of medial temporal lobe volume (via structural MRI) and regional blood flow (via single photon emission CT [SPECT] tracers) is being investigated.17

 

 

The diagnosis of DLB is currently based on the presenting clinical symptoms and the exclusion of other medical conditions whose symptoms mimic those of DLB.7 The screening assessment may include a neurologic/psychiatric assessment (MMSE, psychiatric evaluation, and interviews with family members or caretakers), neuroimaging such as MRI to rule out other organic causes, and laboratory evaluation to rule out potentially reversible causes of dementia, including electrolyte imbalance, vitamin deficiency (specifically vitamin B12), anemia, thyroid dysfunction, and kidney or liver impairment.18

The American Psychiatric Assocation1 categorizes DLB under “Dementia Due to Other General Medical Conditions” (294.1x). The World Health Organization19 includes it among “Other specified degenerative diseases of the nervous system” (G31.8).

Treatment
Lewy body dementia is an irreversible neurologic degenerative disorder. Treatment for DLB comprises symptom management, primarily through pharmacology; however, the response to medication is highly individualized. Treatment includes management of the following symptoms:

Cognitive impairment. Cholinesterase inhibitors, such as rivastigmine (3 to 12 mg/d), donepezil (10 mg/d), or galantamine (titrated up to 12 mg bid),20-23 improve attention and behavior and reduce apathy, anxiety, delusions, and hallucinations. As cognitive impairment worsens, memantine (10 mg bid) may be effective.24 The potential for anticholinergic adverse effects requires close monitoring in patients taking these agents.

Parkinsonian symptoms. Medications indicated for Parkinson’s disease and syndrome, such as carbidopa-levodopa (25/100 mg tid), can be effective; dosage may be slowly titrated upward as tolerated and if needed for symptom management.25,26 The dopaminergic effect of antiparkinson medications may intensify the psychotic symptoms and worsen the REM sleep pattern. In this case, a low-dose atypical antipsychotic is suggested27,28 (see below).

Psychotic symptoms. An atypical antipsychotic agent, such as quetiapine (12.5 mg), risperidone (0.25 mg), olanzapine (2.5 mg), ziprasidone (20 mg), aripiprazole (2 mg), or paliperidone (1.5 mg), may be used. Because of the DLB-associated risk of neuroleptic sensitivity, atypical antipsychotic agents should be initiated at a low dose with slow upward titration17,26,29; quetiapine appears less likely than risperidone or olanzapine to cause neuroleptic sensitivity or to trigger EPS.4 For Asian patients, who often respond to lower doses of these medications (and are more easily affected by associated adverse effects), Chen et al30 recommend a starting dose of about one-half the recommended dose.

Depression. An SSRI antidepressant with relatively simple pharmacologic properties and moderate half-life may be used to manage symptoms of depression.26,31,32 Long–half-life SSRIs (eg, fluoxetine) should be avoided in elderly patients; in response to SNRIs (serotonin-norepinephrine reuptake inhibitors), these patients may experience elevated blood pressures and pulses, with subsequent morbidity.33

REM sleep disturbances. Clo­nazepam (0.25 mg), melatonin (3.0 mg), or quetiapine (12.5 mg) may be administered at bedtime.34

Important Lessons
In general, providers should consider the benefits and risks of any pharmacologic treatment and avoid polypharmacy, if possible. Family and caretakers should be included in the treatment planning, with a focus on prioritizing and managing the most debilitating symptoms or dysfunctions that prompt concerns for safety.

For optimal homeostasis, some DLB patients may require joint pharmacologic modalities that appear counterintuitive—for example, an antiparkinsonism (dopaminergic) agent for parkinsonian symptoms or neuroleptic-induced EPS, versus an antipsychotic (eg, a dopamine antagonist) to treat profound hallucinations.26

As the response to treatment for DLB is highly individualized, it is essential to titrate and augment with care.

CONCLUSION
In DLB, as with other dementing illnesses, the onset of symptoms can be gradual and insidious, posing a great challenge to the clinician who seeks to confirm the diagnosis. In the illness’s early stages, the clinician may have to treat targeted symptoms and adjust the treatment plan once signs of the pathologic origins emerge.

It is critical to understand the mechanisms of psychotropic medications and targeted neurotransmitters when evaluating treatment for DLB. Titrating or augmenting these medications in elderly patients requires the clinician to follow a principle of start low and go slow, making only one change at a time.

It is always helpful to include family members in the patient’s care and to gather information on previous history, personality traits, family history, and cultural components. It is also important to communicate with other specialists to implement collaborative care.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text revision). Washington, DC: American Psychiatric Association; 2000:167.

2. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). www.atlantapsychia try.com/forms/AIMS.pdf. Accessed May 20, 2010.

3. Mini–Mental State Examination. www.nmaging .state.nm.us/pdf_files/Mini_Mental_Status_Exam.pdf. Accessed May 20, 2010.

4. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 suppl 11:16-22.

5. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007;27(1):42-47.

6. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 suppl):417-423.

7. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47(5):1113-1124.

8. Hill C, Reiss N. Lewy body dementia (2008). www.mentalhelp.net/poc/view_doc.php?type=doc& id=13151&cn=231. Accessed May 20, 2010.

9. Lewy Body Dementia Association, Inc. Lewy body dementia: current issues in diagnosis and treatment. www.lewybodydementia.org. Accessed May 20, 2010.

10. Varanese S, Perfetti B, Monaco D, et al. Fluctuating cognition and different cognitive and behavioural profiles in Parkinson’s disease with dementia: comparison of dementia with Lewy bodies and Alzheimer’s disease. J Neurol. 2010 Jan 22. [Epub ahead of print]

11. Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disorder. 2010;25(2):167-171.

12. Gagnon JF, Postuma RB, Mazza S, et al. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5(5):424-432.

13. Dodel R, Csoti I, Ebersbach G, et al. Lewy body dementia and Parkinson’s disease with dementia. J Neurol. 2008;255 suppl 5:39-47.

14. Sonnesyn H, Nilsen DW, Rongve A, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307-313.

15. Kenny RA, Shaw FE, O’Brien JT, et al. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry. 2004;75(7):966-971.

16. Hickey C, Chisholm T, Passmore MJ, et al. Differentiating the dementias: revisiting synucleinopathies and tauopathies. Curr Alzheimer Res. 2008;5(1):52-60.

17. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry. 2003; 8(1):46-57.

18. Bird TD, Miller BL. Dementia. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical; 2008:2536-2549.

19. World Health Organization. International Classification of Diseases (ICD), Version 2007. Chapter VI: Diseases of the Central Nervous System. http://apps.who.int/classifications/apps/icd/icd10online/index.htm?kg00.htm+. Accessed May 20, 2010.

20. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036.

21. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s disease and Alzheimer’s disease: similarities and differences. J Alzheimers Dis. 2007;11(4):509-519.

22. Lam B, Hollingdrake E, Kennedy JL, et al. Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics. 2009;4(2):91-106.

23. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;(3):CD003672.

24. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618.

25. Merck & Co., Inc. Sinemet® CR (carbidopa-levodopa) sustained-release tablets. http://packageinserts.bms.com/pi/pi_sinemet_cr.pdf. Accessed May 20, 2010.

26. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027-2037.

27. Kato K, Wada T, Kawakatsu S, Otani K. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):201-203.

28. Yamauchi K, Takehisa M, Tsuno M, et al. Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. Gen Hosp Psychiatry. 2003;25(2):140-142.

29. Stahl SM. The Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge University Press; 2006:459.

30. Chen JP, Barron C, Lin KM, Chung H. Prescribing medication for Asians with mental disorders. West J Med. 2002;176(4):271-275.

31. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.

32. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465.

33. Schwab W, Messinger-Rapport B, Franco K. Psychiatric symptoms of dementia: treatable, but no silver bullet. Cleve Clin J Med. 2009;76(3):167-174.

34. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742-747

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (text revision). Washington, DC: American Psychiatric Association; 2000:167.

2. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). www.atlantapsychia try.com/forms/AIMS.pdf. Accessed May 20, 2010.

3. Mini–Mental State Examination. www.nmaging .state.nm.us/pdf_files/Mini_Mental_Status_Exam.pdf. Accessed May 20, 2010.

4. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 suppl 11:16-22.

5. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007;27(1):42-47.

6. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 suppl):417-423.

7. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47(5):1113-1124.

8. Hill C, Reiss N. Lewy body dementia (2008). www.mentalhelp.net/poc/view_doc.php?type=doc& id=13151&cn=231. Accessed May 20, 2010.

9. Lewy Body Dementia Association, Inc. Lewy body dementia: current issues in diagnosis and treatment. www.lewybodydementia.org. Accessed May 20, 2010.

10. Varanese S, Perfetti B, Monaco D, et al. Fluctuating cognition and different cognitive and behavioural profiles in Parkinson’s disease with dementia: comparison of dementia with Lewy bodies and Alzheimer’s disease. J Neurol. 2010 Jan 22. [Epub ahead of print]

11. Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disorder. 2010;25(2):167-171.

12. Gagnon JF, Postuma RB, Mazza S, et al. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5(5):424-432.

13. Dodel R, Csoti I, Ebersbach G, et al. Lewy body dementia and Parkinson’s disease with dementia. J Neurol. 2008;255 suppl 5:39-47.

14. Sonnesyn H, Nilsen DW, Rongve A, et al. High prevalence of orthostatic hypotension in mild dementia. Dement Geriatr Cogn Disord. 2009;28(4):307-313.

15. Kenny RA, Shaw FE, O’Brien JT, et al. Carotid sinus syndrome is common in dementia with Lewy bodies and correlates with deep white matter lesions. J Neurol Neurosurg Psychiatry. 2004;75(7):966-971.

16. Hickey C, Chisholm T, Passmore MJ, et al. Differentiating the dementias: revisiting synucleinopathies and tauopathies. Curr Alzheimer Res. 2008;5(1):52-60.

17. McKeith IG, Burn DJ, Ballard CG, et al. Dementia with Lewy bodies. Semin Clin Neuropsychiatry. 2003; 8(1):46-57.

18. Bird TD, Miller BL. Dementia. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical; 2008:2536-2549.

19. World Health Organization. International Classification of Diseases (ICD), Version 2007. Chapter VI: Diseases of the Central Nervous System. http://apps.who.int/classifications/apps/icd/icd10online/index.htm?kg00.htm+. Accessed May 20, 2010.

20. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-2036.

21. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson’s disease and Alzheimer’s disease: similarities and differences. J Alzheimers Dis. 2007;11(4):509-519.

22. Lam B, Hollingdrake E, Kennedy JL, et al. Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics. 2009;4(2):91-106.

23. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;(3):CD003672.

24. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-618.

25. Merck & Co., Inc. Sinemet® CR (carbidopa-levodopa) sustained-release tablets. http://packageinserts.bms.com/pi/pi_sinemet_cr.pdf. Accessed May 20, 2010.

26. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027-2037.

27. Kato K, Wada T, Kawakatsu S, Otani K. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):201-203.

28. Yamauchi K, Takehisa M, Tsuno M, et al. Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease. Gen Hosp Psychiatry. 2003;25(2):140-142.

29. Stahl SM. The Prescriber’s Guide: Stahl’s Essential Psychopharmacology. Cambridge University Press; 2006:459.

30. Chen JP, Barron C, Lin KM, Chung H. Prescribing medication for Asians with mental disorders. West J Med. 2002;176(4):271-275.

31. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.

32. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465.

33. Schwab W, Messinger-Rapport B, Franco K. Psychiatric symptoms of dementia: treatable, but no silver bullet. Cleve Clin J Med. 2009;76(3):167-174.

34. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742-747

Issue
Clinician Reviews - 20(6)
Issue
Clinician Reviews - 20(6)
Page Number
13-17
Page Number
13-17
Publications
Publications
Topics
Article Type
Display Headline
Woman, 80, With Hallucinations and Tremors
Display Headline
Woman, 80, With Hallucinations and Tremors
Legacy Keywords
Lewy body, dementia, hallucinations, tremorsLewy body, dementia, hallucinations, tremors
Legacy Keywords
Lewy body, dementia, hallucinations, tremorsLewy body, dementia, hallucinations, tremors
Sections
Disallow All Ads
Alternative CME

Emergent Management of Bite Wounds

Article Type
Changed
Display Headline
Emergent Management of Bite Wounds

Article PDF
Author and Disclosure Information

Jason J. Hansen, DO, and Azeemuddin Ahmed, MD, MBA

Issue
Emergency Medicine - 42(6)
Publications
Topics
Page Number
6-11
Legacy Keywords
bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management
Sections
Author and Disclosure Information

Jason J. Hansen, DO, and Azeemuddin Ahmed, MD, MBA

Author and Disclosure Information

Jason J. Hansen, DO, and Azeemuddin Ahmed, MD, MBA

Article PDF
Article PDF

Issue
Emergency Medicine - 42(6)
Issue
Emergency Medicine - 42(6)
Page Number
6-11
Page Number
6-11
Publications
Publications
Topics
Article Type
Display Headline
Emergent Management of Bite Wounds
Display Headline
Emergent Management of Bite Wounds
Legacy Keywords
bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management
Legacy Keywords
bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management bite wounds, dog bites, cat bites, human bites, rodent bites, infections, rabies, wound care, irrigation, antibiotics, pain management
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Intrathecal Administration Errors

Article Type
Changed
Display Headline
Intrathecal Administration Errors

Article PDF
Author and Disclosure Information

Lewis S. Nelson, MD (Series Editor), Daniel M. Lugassy, MD, and David H. Jang, MD

Issue
Emergency Medicine - 42(6)
Publications
Topics
Page Number
12-16
Legacy Keywords
intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid
Sections
Author and Disclosure Information

Lewis S. Nelson, MD (Series Editor), Daniel M. Lugassy, MD, and David H. Jang, MD

Author and Disclosure Information

Lewis S. Nelson, MD (Series Editor), Daniel M. Lugassy, MD, and David H. Jang, MD

Article PDF
Article PDF

Issue
Emergency Medicine - 42(6)
Issue
Emergency Medicine - 42(6)
Page Number
12-16
Page Number
12-16
Publications
Publications
Topics
Article Type
Display Headline
Intrathecal Administration Errors
Display Headline
Intrathecal Administration Errors
Legacy Keywords
intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid
Legacy Keywords
intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid intrathecal chemotherapy, cerebrospinal fluid, central nervous system, neurotoxicity, benzyl alcohol, vincristine, Ommaya reservoir, dexamethasone, glutamic acid, pyridoxine, folinic acid
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Treatment of Distal Biceps Tendon Ruptures

Article Type
Changed
Display Headline
Treatment of Distal Biceps Tendon Ruptures

Article PDF
Author and Disclosure Information

Benjamin J. Widmer, MD, and Robert Z. Tashjian, MD

Dr. Widmer is Resident, and Dr. Tashjian is Assistant Professor, Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, Utah.

Issue
The American Journal of Orthopedics - 39(6)
Publications
Topics
Page Number
288-296
Legacy Keywords
distal, biceps, tendon, rupture, traumatic injury, soft-tissue, partial ruptures, reconstruction, allograft, autograft, grafts, sutur anchors, endobutton, chronic ruptures, ajo, american journal of orthopedics, Widmer, Tashjian
Sections
Author and Disclosure Information

Benjamin J. Widmer, MD, and Robert Z. Tashjian, MD

Dr. Widmer is Resident, and Dr. Tashjian is Assistant Professor, Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, Utah.

Author and Disclosure Information

Benjamin J. Widmer, MD, and Robert Z. Tashjian, MD

Dr. Widmer is Resident, and Dr. Tashjian is Assistant Professor, Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, Utah.

Article PDF
Article PDF

Issue
The American Journal of Orthopedics - 39(6)
Issue
The American Journal of Orthopedics - 39(6)
Page Number
288-296
Page Number
288-296
Publications
Publications
Topics
Article Type
Display Headline
Treatment of Distal Biceps Tendon Ruptures
Display Headline
Treatment of Distal Biceps Tendon Ruptures
Legacy Keywords
distal, biceps, tendon, rupture, traumatic injury, soft-tissue, partial ruptures, reconstruction, allograft, autograft, grafts, sutur anchors, endobutton, chronic ruptures, ajo, american journal of orthopedics, Widmer, Tashjian
Legacy Keywords
distal, biceps, tendon, rupture, traumatic injury, soft-tissue, partial ruptures, reconstruction, allograft, autograft, grafts, sutur anchors, endobutton, chronic ruptures, ajo, american journal of orthopedics, Widmer, Tashjian
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

UPDATE: INFECTIOUS DISEASE

Article Type
Changed
Display Headline
UPDATE: INFECTIOUS DISEASE

Six recent articles stand out in the field of infectious disease:

  • an assessment of outcomes of seriously ill patients who were hospitalized early in the course of the H1N1 influenza epidemic. The authors highlight major differences in the epidemiology of this infection, compared with regular seasonal flu
  • an examination of outcomes of pregnant women who developed H1N1 influenza
  • an exploration of the use of blunt needles during cesarean delivery to prevent glove perforation
  • an evaluation of the utility of prophylactic antibiotics in ostensibly low-risk women undergoing scheduled cesarean delivery
  • a look at the timing of antibiotic prophylaxis for cesarean delivery
  • a comparison of skin preparation techniques in the prevention of surgical-site infection.

The focus on cesarean delivery in most of these studies seems particularly appropriate, now that this operation has become the most frequently performed major surgical procedure in US hospitals.

H1N1 virus hits hardest during pregnancy and chronic illness

Jain S, Kamimoto L, Bramley AM, et al, for 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935–1944.

This retrospective survey of patients hospitalized for at least 24 hours for treatment of influenza-like illness included 272 patients who were given a diagnosis of H1N1 influenza, based on real-time, reverse-transcriptase, polymerase chain reaction assay. Sixty-seven (25%) of these patients were admitted to an ICU, and 19 (7%) died. All of the patients who died had been treated in an ICU, and two thirds had an underlying medical condition. Three of the deaths involved pregnant women. None of the patients who died received antiviral therapy within 48 hours of the onset of symptoms. Those who died were also less likely to have been vaccinated against seasonal influenza in 2008–2009.

Details of the trial

The 272 patients included in this study sample represented 25% of the total number of patients hospitalized in the United States for treatment of influenza between April and mid-June 2009. They exhibited the following characteristics:

  • median age: 21 years
  • race and ethnicity: 30% were Hispanic, and 27% were non-Hispanic white
  • most common symptoms: fever and cough, although diarrhea or vomiting was reported in 39% of patients
  • underlying medical illness: present in 73% (198 patients), including 60% of children and 83% of adults. At least two underlying medical conditions were present in 32% of patients. Asthma was the most common comorbid condition
  • pregnancy: 18 patients were pregnant. Four of the pregnant patients also had asthma, and two had diabetes
  • obesity: 29% of adults were obese. Morbid obesity was present in 26%. More than 75% of obese and morbidly obese patients had at least one underlying medical illness
  • bloodwork at admission: 20% of patients were leukopenic; 37% were anemic; and 14% were thrombocytopenic
  • chest film: 40% of patients who underwent chest radiography had findings consistent with pneumonia. Findings included bilateral infiltrates in 66 patients, a unilobar infiltrate in 26, and multilobar infiltrates in two
  • antiviral therapy: 75% ultimately received antiviral drugs, with a median time from onset of illness to initiation of therapy of 3 days (range, 0–29 days). Only 39% received antiviral therapy within 48 hours of the onset of symptoms
  • antibiotic therapy: 79% of patients received antibiotics for presumed superimposed bacterial infection. The most commonly used antibiotics were ceftriaxone, azithromycin, vancomycin, and levofloxacin.

Study offers 4 useful lessons

The study by Jain and colleagues offers clinically applicable lessons:

  • it reinforces the point that children and young adults, including pregnant women, are at increased risk of serious morbidity and mortality
  • it demonstrates that most seriously affected patients have at least one underlying medical condition, such as asthma
  • it highlights the importance of pregnancy and morbid obesity as major conditions that contribute to serious complications from influenza. The 7% prevalence of pregnant patients is significantly higher than the 1% prevalence that would typically be expected with seasonal influenza. Similarly, the 26% prevalence of morbid obesity greatly exceeds the estimated 5% prevalence in the adult US population
  • it confirms the importance of treating patients early in the course of their illness with antiviral drugs such as oseltamivir. Notably, none of the patients who died received treatment within 48 hours of the onset of illness, when the drugs are most likely to be effective.

How to treat H1N1 influenza

The vast majority of strains of the 2009 H1N1 virus are susceptible to oseltamivir and zanamivir, but essentially all strains are resistant to amantadine and rimantadine.1 Therefore, all individuals who are hospitalized should be treated with one of two regimens:

  • oseltamivir, 75 mg orally, twice daily for at least 5 days
  • zanamivir, 10 mg by inhalation, twice daily for at least 5 days.
 

 

These same regimens should be used for outpatients who are at high risk of complications.

Ideally, antiviral treatment should be administered within 48 hours of the onset of symptoms, but do not withhold treatment even if more than 48 hours have elapsed since the onset of illness.2,3

Both oseltamivir and zanamivir are also effective for prevention of infection in susceptible patients who have been exposed to H1N1 influenza. The appropriate dosage of oseltamivir for prophylaxis is 75 mg orally once daily for 10 days. The corresponding dosage of zanamivir is 10 mg by inhalation once daily for 10 days.1

The most effective method of prophylaxis, of course, is vaccination with the new H1N1 vaccine.4 There are two forms of the vaccine—a live virus nasal vaccine and an inactivated vaccine for intramuscular administration. Pregnant women should receive only the inactivated vaccine.

The key reservoirs of all influenza A viruses are migrating waterfowl, pigs, and humans. The current H1N1 strain of virus contains eight unique RNA segments that are a mixture of components from avian, pig, and human influenza viruses.2 The pandemic resulting from this virus is unusual because the continent of origin was North America (Mexico) rather than Asia, the season of origin was spring rather than fall, and the patients at greatest risk of dying have been children and young adults rather than infants and the elderly.3

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Women who are pregnant or planning to become pregnant should be vaccinated against H1N1 influenza. Use the inactivated virus if a woman is already pregnant.

After exposure to H1N1 influenza, unvaccinated pregnant women and other patients at high risk of developing the virus should be given oseltamivir or zanamivir prophylactically, using the dosage and route of administration described above for prophylaxis.

Pregnant women and other high-risk patients who exhibit symptoms of H1N1 influenza should be given oseltamivir or zanamivir, using the dosage and route of administration described above for treatment, ideally within 48 hours of the onset of symptoms.

For pregnant and postpartum patients, base treatment of H1N1 flu on symptoms, not rapid tests

Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362(1):27–35.

Louie and coworkers describe the outcome of a statewide surveillance program by the California Department of Public Health. They reviewed the medical records of 94 pregnant women, eight women who were within the first 2 weeks postpartum, and 137 nonpregnant women of reproductive age who were hospitalized with confirmed 2009 H1N1 influenza between April 23 and August 11, 2009.

Eighteen pregnant women and four postpartum patients (22%) required intensive care, and 16 (73%) of these women had to be ventilated mechanically. Of the 18 pregnant women who required treatment in the ICU, 12 delivered in the hospital, and four underwent emergent cesarean delivery in the ICU.

Eight (8%) of the 102 pregnant and postpartum patients died. None of these eight women received antiviral therapy within 48 hours of the onset of symptoms. In fact, for pregnant and postpartum patients, a delay in administration of antiviral therapy beyond 48 hours after the onset of symptoms produced a 4.3 relative risk of death (95% confidence interval [CI], 1.4–13.7), compared with patients who were treated early in the course of their infection.

Details of the trial

The women in this trial had the following characteristics:

  • gestational age: five (5%) of the 94 pregnant women were in the first trimester, 35 (37%) were in the second trimester, and 54 (57%) were in the third trimester
  • underlying conditions were present in 34% of the pregnant and postpartum women and 60% of nonpregnant women. These conditions placed them at increased risk of complications from influenza. The most common underlying condition was asthma
  • antiviral therapy was administered to approximately 80% of both pregnant and nonpregnant women. However, only 50% of pregnant women and 34% of nonpregnant women received treatment within 48 hours of the onset of symptoms
  • antibiotic therapy was given to 45% of pregnant women and 58% of nonpregnant women for presumed secondary bacterial infection
  • false-negative test results: 153 women underwent rapid tests for influenza, 38% of which were falsely negative.

Treat pregnant patients expediently

This article is an excellent complement to the study by Jain and colleagues described on page 37. It strikingly illustrates the heightened risk of morbidity and mortality that pregnant women face when they develop H1N1 influenza. Louie and coworkers documented an influenza-specific mortality ratio (maternal deaths for every 100,000 live births) of 4.3. They also provide clear evidence of the perils of relying on rapid diagnostic tests and withholding antiviral treatment if the rapid test is negative. In their series, 38% of rapid tests were falsely negative. In pregnant women, when antiviral therapy was delayed more than 48 hours, the relative risk of death was 4.3, compared with patients who were treated within 48 hours of the onset of symptoms.

 

 

WHAT THIS EVIDENCE MEANS FOR PRACTICE

If there is a clinical suspicion of influenza in a pregnant or postpartum patient, treat her immediately with one of the antiviral regimens outlined on page 38—regardless of the outcome of the rapid test for influenza.

Blunt needles reduce needle sticks during cesarean delivery

Sullivan S, Williamson B, Wilson LK, Korde JE, Soper D. Blunt needles for reduction of needlestick injuries during cesarean delivery. Obstet Gynecol. 2009;114 (2 Pt 1):211–216.

Using glove perforation as a proxy for needlestick injuries, Sullivan and colleagues compared blunt needles with sharp needles during cesarean delivery. Ninety-seven women had all anatomic layers reapproximated using blunt needles, and 97 had them reapproximated using sharp needles. The overall glove perforation rate was 12.3%. For sharp needles, the perforation rate was 17.5%, and for blunt needles it was 7.2% (relative risk [RR], 0.66; 95% CI, 0.49–0.89). The key protective effect of the blunt needles was confined to the assistant surgeon (RR, 0.54; 95% CI, 0.41–0.71). The RR for glove perforation involving the primary surgeon was 0.8 (95% CI, 0.53–1.2).

Details of the trial

Glove type, number of gloves, needle size, and type and gauge of suture material were left to the discretion of the surgeon. Glove perforations were identified by filling the gloves with 1,000 mL of water and applying pressure to the palm and each finger. The secondary endpoint of the study was physician satisfaction with the needle. Primary and assistant surgeons reported comparable levels of dissatisfaction with blunt needles, compared with sharp needles (P < .001). However, 92% of primary surgeons and 93% of assistant surgeons rated the blunt needles as at least “acceptable” for use.

Needle stick has led to hepatitis B transmission

Earlier studies reported a rate of glove perforation of 20% to 26% during open abdominal procedures. In an investigation at our center, we noted glove perforation in 13% of cesarean deliveries.5 In this and another investigation, the frequency of perforation did not vary with the level of training of the surgeon or time of day of the procedure.5,6 The most common sites of perforation were the thumb, index finger, and middle finger of the non-dominant hand. The most common mechanism of injury was handling the needle with the operator’s gloved hand rather than with an instrument.

Double-gloving significantly reduces the risk of injury to the inner glove and, subsequently, to the surgeon’s skin. (Note: Double-gloving does not decrease tactile sensation or increase the risk of mishap.6)

The study by Sullivan and colleagues demonstrates that use of blunt needles offers an additional measure of protection against a penetrating injury to the surgeon’s bare skin. Although no surgeon has yet contracted HIV infection from a surgical needle, the transmission of hepatitis B via contaminated surgical needle has been well documented.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Prudence dictates that we use all proven measures to prevent intraoperative blood exposure. Use of blunt needles should be added to interventions such as double-gloving and use of a neutral zone in which to pass sharp objects.

Prophylactic antibiotics reduce postcesarean infection, even in low-risk women

Dinsmoor MJ, Gilbert S, Landon MB, et al, for Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. Obstet Gynecol. 2009;114(4):752–756.

Infection is the most common postoperative complication of cesarean delivery, now the most frequently performed major operation in America. The principal infection is endometritis, followed by wound infection and urinary tract infection. The frequency of wound infection is on the rise because of the steadily increasing prevalence of obesity in the obstetric population.

Dinsmoor and coworkers conducted this secondary analysis using data from an earlier observational study of 9,432 women who underwent cesarean delivery before the onset of labor. Of these women, 6,006 (64%) received antibiotic prophylaxis.

Women treated prophylactically had a significantly lower rate of endometritis (adjusted odds ratio [OR], 0.40; 95% CI, 0.28–0.59) and of wound infection (adjusted OR, 0.49; 95% CI, 0.28–0.86). The frequency of other infection-related complications was not significantly reduced (adjusted OR, 0.39; 95% CI, 0.13–1.12).

Overall, the size of the effect for endometritis was small; endometritis developed in 2.0% of women in the group that received prophylaxis and 2.6% of women in the group that did not. The size of the effect was even smaller for wound infection.

In this uncontrolled series, 113 patients had to be treated to prevent one case of endometritis or wound infection.

Details of the trial

The original observational study from which this analysis derives was performed by the Maternal-Fetal Medicine Units Network at 13 centers in 1999–2000. The choice of antibiotics and the timing of administration were left to the discretion of the attending physician.

 

 

Principal endpoints were the occurrence of postoperative endometritis and wound infection. Secondary endpoints were less common infection-related complications such as maternal sepsis, fascial dehiscence or evisceration, necrotizing fasciitis, pelvic abscess, and septic pelvic vein thrombophlebitis.

Of the women who were given prophylactic antibiotics, 88% received only a cephalosporin, 7% received only a broad-spectrum penicillin, and 6% received other regimens. Approximately 1% of patients received more than one antibiotic for prophylaxis.

Averting infection pays dividends

More than 90% of patients who have endometritis respond promptly to broad-spectrum antibiotic therapy. However, some women with postcesarean endometritis develop serious complications such as septic shock, septic pelvic vein thrombophlebitis, and pelvic abscess.

Treatment of wound infection is not so straightforward as treatment of endometritis. Wound infections may well require surgical intervention to drain an incisional abscess. They also necessitate a change in antibiotic therapy, and they are one of the two most important risk factors for fascial dehiscence and intestinal evisceration.

Multiple studies have confirmed that antibiotic prophylaxis significantly reduces the risk of endometritis and wound infection in women who undergo cesarean after the start of labor, with or without ruptured membranes.7,8 Recent publications have also demonstrated that prophylaxis before the start of surgery offers a greater protective effect than administration after the infant’s umbilical cord is clamped.9,10 Other investigations have demonstrated that broader-spectrum prophylaxis further improves outcomes in women undergoing cesarean delivery.11,12

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the frequency of postcesarean endometritis and wound infection, even in very low-risk patients. I strongly support the use of prophylactic antibiotics in all women undergoing cesarean delivery. I believe that the best available evidence supports the use of cefazolin (1 g) plus azithromycin (500 mg), administered intravenously before the start of surgery.9-12

Administer antibiotics before making the incision for greatest effectiveness

Owens SM, Brozanski BS, Meyn LA, Wisenfeld HC. Antimicrobial prophylaxis for cesarean delivery before skin incision. Obstet Gynecol. 2009;114(3):573–579.

In this retrospective investigation, Owens and colleagues compared antibiotic prophylaxis in two groups of women undergoing cesarean delivery:

  • 4,229 women who received antibiotics after the infant’s umbilical cord was clamped, from July 2002 to November 2004 (Group 1)
  • 4,781 women who received antibiotics before the skin was incised, from June 2005 to August 2007 (Group 2).

Both scheduled and unscheduled cesarean deliveries were included, as were women who received antibiotics intrapartum for group B streptococcus prophylaxis and treatment of chorioamnionitis. The most commonly used antibiotic was intravenous cefazolin (1 g).

After excluding women who received group B streptococcus prophylaxis or intrapartum treatment of chorioamnionitis, the authors demonstrated a nearly 50% reduction in the rate of endometritis among women who received antibiotics before surgery (OR, 0.54; 95% CI, 0.38–0.75). They also documented a 30% reduction in the rate of wound infection in these patients (OR, 0.72; 95% CI, 0.55–0.46).

Details of the trial

Principal outcome measures were the rates of maternal endometritis and wound infection and rates of proven and presumed neonatal infection. The mean age and racial distribution were similar in the two groups, but the percentage of patients treated on a resident teaching service was lower in Group 2 (14.9% vs. 18.9%; P < .001). The two groups did not differ in mean body mass index or in the percentage of patients who were in labor before surgery. Colonization with group B streptococcus was more common in Group 2 (24.4% vs. 22.2%; P = .5). However, chorioamnionitis was less prevalent in Group 2 (5.6% vs. 10.3%; P < .001).

The rates of culture-proven neonatal infection within the first 3 days of life (early-onset infection) were similar between groups (1.3% in Group 1 vs. 0.7% in Group 2). Culture-proven late-onset neonatal infection was less common in Group 2 (1.8% vs. 5.7%; P < .001). The groups did not differ in the proportion of newborns treated for presumed infection (24.1% in Group 1 vs. 22.2% in Group 2).

Plentiful data confirm the superiority of preoperative administration

Endometritis is the most common postoperative complication associated with cesarean delivery. Wound infection is less common but more likely to lead to prolonged postoperative morbidity and extended hospitalization. Reducing both of these complications is a critical clinical objective.

Virtually without exception, every investigation has confirmed that prophylactic antibiotics reduce the frequency of postcesarean endometritis and, usually, wound infection as well. One dose of a given antibiotic is clearly as effective as multiple doses.

Classic animal investigations by Burke demonstrated that prophylaxis was most effective when antibiotics were present in tissue prior to the surgical incision.13 Nevertheless, early investigators in obstetrics argued that preoperative exposure to antibiotics increased the likelihood that the neonate would require an evaluation for sepsis and that delaying antibiotics until after cord clamping did not compromise the effectiveness of prophylaxis.14,15

 

 

Sullivan and colleagues were the first authors to successfully challenge this dictum.9 In a well-designed investigation, they demonstrated that preoperative administration of antibiotics significantly reduces the frequency of endometritis (RR, 0.22) but not wound infection, and does not increase the need for neonatal sepsis evaluation. Kaimel and coworkers later confirmed these findings,16 and this study by Owen and associates offers additional proof of the effectiveness and safety of preoperative antibiotic administration.

I offer only one addendum to the conclusions presented by Owen and colleagues. Two recent investigations from the University of Alabama conclusively demonstrate that, by extending the spectrum of antibiotic coverage by combining azithromycin and cefazolin, we can further reduce postcesarean endometritis and wound infection.11,17 Accordingly, at our center, we now administer both intravenous (IV) azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the rates of postcesarean endometritis and wound infection, and preoperative administration is superior to administration after cord clamping. Preoperative administration is also safe for the neonate.

Administer IV azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

Chlorhexidine solutions are superior to povidone-iodine for surgical-site antisepsis

Darouiche RO, Wall MJ, Itani KMF, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362(1):18–26.

This report is an excellent complement to the two studies discussed above, which focused on systemic antibiotic prophylaxis for the prevention of postcesarean infection. Here, Darouiche and colleagues conducted a randomized, prospective, unblinded, multi-center comparison of two skin preparations to prevent surgical-site infection:

  • 2% chlorhexidine gluconate and 70% isopropyl alcohol (409 patients)
  • 10% povidone-iodine solution (440 patients).

Participants underwent a variety of abdominal and nonabdominal (thoracic, gynecologic, and urologic) procedures. All patients received systemic antibiotic prophylaxis within 1 hour before the start of surgery.

The primary outcome measure was the occurrence of any surgical-site infection up to 30 days after surgery. This rate was lower among patients who received chlorhexidine-alcohol skin preparations than among those who received povidone-iodine (9.5% vs. 16.1%; P = .004).

Secondary endpoints were specific types of infection:

  • superficial incisional infection (skin and subcutaneous tissue): lower among patients receiving chlorhexidine-alcohol (4.2% vs. 8.6%; P = .008)
  • deep incisional infection (involving fascia and muscle): lower among patients receiving chlorhexidine-alcohol (1% vs. 3%; P = .05)
  • organ-space infection (any organ or space other than the body wall): no significant difference between women treated with chlorhexidine-alcohol and those treated with povidone-iodine.

Seventeen patients would need to be treated with chlorhexidine-alcohol to prevent one surgical-site infection.

Chlorhexidine has a solid track record

The 41% reduction in the rate of surgical-site infection with chlorhexidine-alcohol (RR, 0.59; 95% CI, 0.41–0.85) is consistent with a 49% reduction in the risk of vascular catheter-related bacteremia using the same formulation.18 The findings are also consistent with a recent report showing that chlorhexidine was more effective than iodine-containing solutions in reducing bacterial concentration in the operative field in women undergoing vaginal hysterectomy.19

Darouiche and coworkers suggest that chlorhexidine is more effective because it has a more rapid onset of action and greater and more persistent antibacterial activity despite exposure to body fluids. Quite appropriately, they indicate that the solution used in their study is flammable, but they observed no adverse effects in a large sample of patients undergoing a variety of procedures.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

I strongly recommend that chlorhexidine be used for all surgical skin preparation in obstetric and gynecologic patients. this intervention, along with consistent use of systemic antibiotic prophylaxis, should be highly effective in reducing the risk of superficial and deep abdominal wound infection.

References

1. Antiviral drugs for influenza. The Medical Letter. 2009;51(1325):89-92.

2. Wenzel RP, Edmond MB. Preparing for 2009 H1N1 influenza. N Engl J Med. 2009;361(20):1991-1993.

3. Perez-Padilla R, Rosa-Zambori D, deLeon SP, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.

4. H1N1 vaccine for prevention of pandemic influenza. The Medical Letter. 2009;51(1322):77-78.

5. Chapman S, Duff P. Frequency of glove perforations and subsequent blood contact in association with selected obstetric surgical procedures. Am J Obstet Gynecol. 1993;168(5):1354-1357.

6. Lancaster C, Duff P. Single versus double-gloving for obstetric and gynecologic procedures. Am J Obstet Gynecol. 2007;196(5):e36-e37.

7. Smaill F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section. Cochrane Database of Systematic Reviews. 2002;(3):CD000933.-doi:10/1002/14651858.

8. Prophylactic antibiotics in labor and delivery. ACOG Practice Bulletin No. 47. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2003;102(4):875-882.

9. Sullivan SA, Smith T, Chang F, Hulsey T, Vandorsten JP, Soper D. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized controlled trial. Am J Obstet Gynecol. 2007;196(5):455.e1-e5.

10. Costantine MM, Rahman M, Ghulmiyah L, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol. 2008;199(3):301.e1-e6.

11. Tita ATN, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008;111(1):51-56.

12. Tita AT, Owen J, Stamm AM, Grimes A, Hauth JC, Andrews WW. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol. 2008;199(3):303.e1-e3.

13. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961;50:161-168.

14. Gordon HR, Phelps D, Blanchard K. Prophylactic cesarean section antibiotics: maternal and neonatal morbidity before and after cord clamping. Obstet Gynecol. 1979;53(2):151-156.

15. Cunningham FG, Leveno KJ, DePalma RT, Roark M, Rosenfeld CR. Perioperative antimicrobials for cesarean delivery: before or after cord clamping? Obstet Gynecol. 1983;62(2):151-154.

16. Kaimal AJ, Zlatnik MG, Chang YW, et al. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. Am J Obstet Gynecol. 2008;199(3):310.e1-e5.

17. Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systemic review. Obstet Gynecol. 2009;113(3):675-682.

18. Chaiyakunapruk N, Veerstra DI, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136(11):792-801.

19. Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005;192(2):422-425.

Article PDF
Author and Disclosure Information


Patrick Duff, MD
Dr. Duff is Professor and Residency Program Director, Department of Obstetrics and Gynecology, at the University of Florida College of Medicine in Gainesville, Fla.

Dr. Duff reports no financial relationships relevant to this article.

Issue
OBG Management - 22(06)
Publications
Topics
Page Number
36-46
Sections
Author and Disclosure Information


Patrick Duff, MD
Dr. Duff is Professor and Residency Program Director, Department of Obstetrics and Gynecology, at the University of Florida College of Medicine in Gainesville, Fla.

Dr. Duff reports no financial relationships relevant to this article.

Author and Disclosure Information


Patrick Duff, MD
Dr. Duff is Professor and Residency Program Director, Department of Obstetrics and Gynecology, at the University of Florida College of Medicine in Gainesville, Fla.

Dr. Duff reports no financial relationships relevant to this article.

Article PDF
Article PDF

Six recent articles stand out in the field of infectious disease:

  • an assessment of outcomes of seriously ill patients who were hospitalized early in the course of the H1N1 influenza epidemic. The authors highlight major differences in the epidemiology of this infection, compared with regular seasonal flu
  • an examination of outcomes of pregnant women who developed H1N1 influenza
  • an exploration of the use of blunt needles during cesarean delivery to prevent glove perforation
  • an evaluation of the utility of prophylactic antibiotics in ostensibly low-risk women undergoing scheduled cesarean delivery
  • a look at the timing of antibiotic prophylaxis for cesarean delivery
  • a comparison of skin preparation techniques in the prevention of surgical-site infection.

The focus on cesarean delivery in most of these studies seems particularly appropriate, now that this operation has become the most frequently performed major surgical procedure in US hospitals.

H1N1 virus hits hardest during pregnancy and chronic illness

Jain S, Kamimoto L, Bramley AM, et al, for 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935–1944.

This retrospective survey of patients hospitalized for at least 24 hours for treatment of influenza-like illness included 272 patients who were given a diagnosis of H1N1 influenza, based on real-time, reverse-transcriptase, polymerase chain reaction assay. Sixty-seven (25%) of these patients were admitted to an ICU, and 19 (7%) died. All of the patients who died had been treated in an ICU, and two thirds had an underlying medical condition. Three of the deaths involved pregnant women. None of the patients who died received antiviral therapy within 48 hours of the onset of symptoms. Those who died were also less likely to have been vaccinated against seasonal influenza in 2008–2009.

Details of the trial

The 272 patients included in this study sample represented 25% of the total number of patients hospitalized in the United States for treatment of influenza between April and mid-June 2009. They exhibited the following characteristics:

  • median age: 21 years
  • race and ethnicity: 30% were Hispanic, and 27% were non-Hispanic white
  • most common symptoms: fever and cough, although diarrhea or vomiting was reported in 39% of patients
  • underlying medical illness: present in 73% (198 patients), including 60% of children and 83% of adults. At least two underlying medical conditions were present in 32% of patients. Asthma was the most common comorbid condition
  • pregnancy: 18 patients were pregnant. Four of the pregnant patients also had asthma, and two had diabetes
  • obesity: 29% of adults were obese. Morbid obesity was present in 26%. More than 75% of obese and morbidly obese patients had at least one underlying medical illness
  • bloodwork at admission: 20% of patients were leukopenic; 37% were anemic; and 14% were thrombocytopenic
  • chest film: 40% of patients who underwent chest radiography had findings consistent with pneumonia. Findings included bilateral infiltrates in 66 patients, a unilobar infiltrate in 26, and multilobar infiltrates in two
  • antiviral therapy: 75% ultimately received antiviral drugs, with a median time from onset of illness to initiation of therapy of 3 days (range, 0–29 days). Only 39% received antiviral therapy within 48 hours of the onset of symptoms
  • antibiotic therapy: 79% of patients received antibiotics for presumed superimposed bacterial infection. The most commonly used antibiotics were ceftriaxone, azithromycin, vancomycin, and levofloxacin.

Study offers 4 useful lessons

The study by Jain and colleagues offers clinically applicable lessons:

  • it reinforces the point that children and young adults, including pregnant women, are at increased risk of serious morbidity and mortality
  • it demonstrates that most seriously affected patients have at least one underlying medical condition, such as asthma
  • it highlights the importance of pregnancy and morbid obesity as major conditions that contribute to serious complications from influenza. The 7% prevalence of pregnant patients is significantly higher than the 1% prevalence that would typically be expected with seasonal influenza. Similarly, the 26% prevalence of morbid obesity greatly exceeds the estimated 5% prevalence in the adult US population
  • it confirms the importance of treating patients early in the course of their illness with antiviral drugs such as oseltamivir. Notably, none of the patients who died received treatment within 48 hours of the onset of illness, when the drugs are most likely to be effective.

How to treat H1N1 influenza

The vast majority of strains of the 2009 H1N1 virus are susceptible to oseltamivir and zanamivir, but essentially all strains are resistant to amantadine and rimantadine.1 Therefore, all individuals who are hospitalized should be treated with one of two regimens:

  • oseltamivir, 75 mg orally, twice daily for at least 5 days
  • zanamivir, 10 mg by inhalation, twice daily for at least 5 days.
 

 

These same regimens should be used for outpatients who are at high risk of complications.

Ideally, antiviral treatment should be administered within 48 hours of the onset of symptoms, but do not withhold treatment even if more than 48 hours have elapsed since the onset of illness.2,3

Both oseltamivir and zanamivir are also effective for prevention of infection in susceptible patients who have been exposed to H1N1 influenza. The appropriate dosage of oseltamivir for prophylaxis is 75 mg orally once daily for 10 days. The corresponding dosage of zanamivir is 10 mg by inhalation once daily for 10 days.1

The most effective method of prophylaxis, of course, is vaccination with the new H1N1 vaccine.4 There are two forms of the vaccine—a live virus nasal vaccine and an inactivated vaccine for intramuscular administration. Pregnant women should receive only the inactivated vaccine.

The key reservoirs of all influenza A viruses are migrating waterfowl, pigs, and humans. The current H1N1 strain of virus contains eight unique RNA segments that are a mixture of components from avian, pig, and human influenza viruses.2 The pandemic resulting from this virus is unusual because the continent of origin was North America (Mexico) rather than Asia, the season of origin was spring rather than fall, and the patients at greatest risk of dying have been children and young adults rather than infants and the elderly.3

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Women who are pregnant or planning to become pregnant should be vaccinated against H1N1 influenza. Use the inactivated virus if a woman is already pregnant.

After exposure to H1N1 influenza, unvaccinated pregnant women and other patients at high risk of developing the virus should be given oseltamivir or zanamivir prophylactically, using the dosage and route of administration described above for prophylaxis.

Pregnant women and other high-risk patients who exhibit symptoms of H1N1 influenza should be given oseltamivir or zanamivir, using the dosage and route of administration described above for treatment, ideally within 48 hours of the onset of symptoms.

For pregnant and postpartum patients, base treatment of H1N1 flu on symptoms, not rapid tests

Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362(1):27–35.

Louie and coworkers describe the outcome of a statewide surveillance program by the California Department of Public Health. They reviewed the medical records of 94 pregnant women, eight women who were within the first 2 weeks postpartum, and 137 nonpregnant women of reproductive age who were hospitalized with confirmed 2009 H1N1 influenza between April 23 and August 11, 2009.

Eighteen pregnant women and four postpartum patients (22%) required intensive care, and 16 (73%) of these women had to be ventilated mechanically. Of the 18 pregnant women who required treatment in the ICU, 12 delivered in the hospital, and four underwent emergent cesarean delivery in the ICU.

Eight (8%) of the 102 pregnant and postpartum patients died. None of these eight women received antiviral therapy within 48 hours of the onset of symptoms. In fact, for pregnant and postpartum patients, a delay in administration of antiviral therapy beyond 48 hours after the onset of symptoms produced a 4.3 relative risk of death (95% confidence interval [CI], 1.4–13.7), compared with patients who were treated early in the course of their infection.

Details of the trial

The women in this trial had the following characteristics:

  • gestational age: five (5%) of the 94 pregnant women were in the first trimester, 35 (37%) were in the second trimester, and 54 (57%) were in the third trimester
  • underlying conditions were present in 34% of the pregnant and postpartum women and 60% of nonpregnant women. These conditions placed them at increased risk of complications from influenza. The most common underlying condition was asthma
  • antiviral therapy was administered to approximately 80% of both pregnant and nonpregnant women. However, only 50% of pregnant women and 34% of nonpregnant women received treatment within 48 hours of the onset of symptoms
  • antibiotic therapy was given to 45% of pregnant women and 58% of nonpregnant women for presumed secondary bacterial infection
  • false-negative test results: 153 women underwent rapid tests for influenza, 38% of which were falsely negative.

Treat pregnant patients expediently

This article is an excellent complement to the study by Jain and colleagues described on page 37. It strikingly illustrates the heightened risk of morbidity and mortality that pregnant women face when they develop H1N1 influenza. Louie and coworkers documented an influenza-specific mortality ratio (maternal deaths for every 100,000 live births) of 4.3. They also provide clear evidence of the perils of relying on rapid diagnostic tests and withholding antiviral treatment if the rapid test is negative. In their series, 38% of rapid tests were falsely negative. In pregnant women, when antiviral therapy was delayed more than 48 hours, the relative risk of death was 4.3, compared with patients who were treated within 48 hours of the onset of symptoms.

 

 

WHAT THIS EVIDENCE MEANS FOR PRACTICE

If there is a clinical suspicion of influenza in a pregnant or postpartum patient, treat her immediately with one of the antiviral regimens outlined on page 38—regardless of the outcome of the rapid test for influenza.

Blunt needles reduce needle sticks during cesarean delivery

Sullivan S, Williamson B, Wilson LK, Korde JE, Soper D. Blunt needles for reduction of needlestick injuries during cesarean delivery. Obstet Gynecol. 2009;114 (2 Pt 1):211–216.

Using glove perforation as a proxy for needlestick injuries, Sullivan and colleagues compared blunt needles with sharp needles during cesarean delivery. Ninety-seven women had all anatomic layers reapproximated using blunt needles, and 97 had them reapproximated using sharp needles. The overall glove perforation rate was 12.3%. For sharp needles, the perforation rate was 17.5%, and for blunt needles it was 7.2% (relative risk [RR], 0.66; 95% CI, 0.49–0.89). The key protective effect of the blunt needles was confined to the assistant surgeon (RR, 0.54; 95% CI, 0.41–0.71). The RR for glove perforation involving the primary surgeon was 0.8 (95% CI, 0.53–1.2).

Details of the trial

Glove type, number of gloves, needle size, and type and gauge of suture material were left to the discretion of the surgeon. Glove perforations were identified by filling the gloves with 1,000 mL of water and applying pressure to the palm and each finger. The secondary endpoint of the study was physician satisfaction with the needle. Primary and assistant surgeons reported comparable levels of dissatisfaction with blunt needles, compared with sharp needles (P < .001). However, 92% of primary surgeons and 93% of assistant surgeons rated the blunt needles as at least “acceptable” for use.

Needle stick has led to hepatitis B transmission

Earlier studies reported a rate of glove perforation of 20% to 26% during open abdominal procedures. In an investigation at our center, we noted glove perforation in 13% of cesarean deliveries.5 In this and another investigation, the frequency of perforation did not vary with the level of training of the surgeon or time of day of the procedure.5,6 The most common sites of perforation were the thumb, index finger, and middle finger of the non-dominant hand. The most common mechanism of injury was handling the needle with the operator’s gloved hand rather than with an instrument.

Double-gloving significantly reduces the risk of injury to the inner glove and, subsequently, to the surgeon’s skin. (Note: Double-gloving does not decrease tactile sensation or increase the risk of mishap.6)

The study by Sullivan and colleagues demonstrates that use of blunt needles offers an additional measure of protection against a penetrating injury to the surgeon’s bare skin. Although no surgeon has yet contracted HIV infection from a surgical needle, the transmission of hepatitis B via contaminated surgical needle has been well documented.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Prudence dictates that we use all proven measures to prevent intraoperative blood exposure. Use of blunt needles should be added to interventions such as double-gloving and use of a neutral zone in which to pass sharp objects.

Prophylactic antibiotics reduce postcesarean infection, even in low-risk women

Dinsmoor MJ, Gilbert S, Landon MB, et al, for Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. Obstet Gynecol. 2009;114(4):752–756.

Infection is the most common postoperative complication of cesarean delivery, now the most frequently performed major operation in America. The principal infection is endometritis, followed by wound infection and urinary tract infection. The frequency of wound infection is on the rise because of the steadily increasing prevalence of obesity in the obstetric population.

Dinsmoor and coworkers conducted this secondary analysis using data from an earlier observational study of 9,432 women who underwent cesarean delivery before the onset of labor. Of these women, 6,006 (64%) received antibiotic prophylaxis.

Women treated prophylactically had a significantly lower rate of endometritis (adjusted odds ratio [OR], 0.40; 95% CI, 0.28–0.59) and of wound infection (adjusted OR, 0.49; 95% CI, 0.28–0.86). The frequency of other infection-related complications was not significantly reduced (adjusted OR, 0.39; 95% CI, 0.13–1.12).

Overall, the size of the effect for endometritis was small; endometritis developed in 2.0% of women in the group that received prophylaxis and 2.6% of women in the group that did not. The size of the effect was even smaller for wound infection.

In this uncontrolled series, 113 patients had to be treated to prevent one case of endometritis or wound infection.

Details of the trial

The original observational study from which this analysis derives was performed by the Maternal-Fetal Medicine Units Network at 13 centers in 1999–2000. The choice of antibiotics and the timing of administration were left to the discretion of the attending physician.

 

 

Principal endpoints were the occurrence of postoperative endometritis and wound infection. Secondary endpoints were less common infection-related complications such as maternal sepsis, fascial dehiscence or evisceration, necrotizing fasciitis, pelvic abscess, and septic pelvic vein thrombophlebitis.

Of the women who were given prophylactic antibiotics, 88% received only a cephalosporin, 7% received only a broad-spectrum penicillin, and 6% received other regimens. Approximately 1% of patients received more than one antibiotic for prophylaxis.

Averting infection pays dividends

More than 90% of patients who have endometritis respond promptly to broad-spectrum antibiotic therapy. However, some women with postcesarean endometritis develop serious complications such as septic shock, septic pelvic vein thrombophlebitis, and pelvic abscess.

Treatment of wound infection is not so straightforward as treatment of endometritis. Wound infections may well require surgical intervention to drain an incisional abscess. They also necessitate a change in antibiotic therapy, and they are one of the two most important risk factors for fascial dehiscence and intestinal evisceration.

Multiple studies have confirmed that antibiotic prophylaxis significantly reduces the risk of endometritis and wound infection in women who undergo cesarean after the start of labor, with or without ruptured membranes.7,8 Recent publications have also demonstrated that prophylaxis before the start of surgery offers a greater protective effect than administration after the infant’s umbilical cord is clamped.9,10 Other investigations have demonstrated that broader-spectrum prophylaxis further improves outcomes in women undergoing cesarean delivery.11,12

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the frequency of postcesarean endometritis and wound infection, even in very low-risk patients. I strongly support the use of prophylactic antibiotics in all women undergoing cesarean delivery. I believe that the best available evidence supports the use of cefazolin (1 g) plus azithromycin (500 mg), administered intravenously before the start of surgery.9-12

Administer antibiotics before making the incision for greatest effectiveness

Owens SM, Brozanski BS, Meyn LA, Wisenfeld HC. Antimicrobial prophylaxis for cesarean delivery before skin incision. Obstet Gynecol. 2009;114(3):573–579.

In this retrospective investigation, Owens and colleagues compared antibiotic prophylaxis in two groups of women undergoing cesarean delivery:

  • 4,229 women who received antibiotics after the infant’s umbilical cord was clamped, from July 2002 to November 2004 (Group 1)
  • 4,781 women who received antibiotics before the skin was incised, from June 2005 to August 2007 (Group 2).

Both scheduled and unscheduled cesarean deliveries were included, as were women who received antibiotics intrapartum for group B streptococcus prophylaxis and treatment of chorioamnionitis. The most commonly used antibiotic was intravenous cefazolin (1 g).

After excluding women who received group B streptococcus prophylaxis or intrapartum treatment of chorioamnionitis, the authors demonstrated a nearly 50% reduction in the rate of endometritis among women who received antibiotics before surgery (OR, 0.54; 95% CI, 0.38–0.75). They also documented a 30% reduction in the rate of wound infection in these patients (OR, 0.72; 95% CI, 0.55–0.46).

Details of the trial

Principal outcome measures were the rates of maternal endometritis and wound infection and rates of proven and presumed neonatal infection. The mean age and racial distribution were similar in the two groups, but the percentage of patients treated on a resident teaching service was lower in Group 2 (14.9% vs. 18.9%; P < .001). The two groups did not differ in mean body mass index or in the percentage of patients who were in labor before surgery. Colonization with group B streptococcus was more common in Group 2 (24.4% vs. 22.2%; P = .5). However, chorioamnionitis was less prevalent in Group 2 (5.6% vs. 10.3%; P < .001).

The rates of culture-proven neonatal infection within the first 3 days of life (early-onset infection) were similar between groups (1.3% in Group 1 vs. 0.7% in Group 2). Culture-proven late-onset neonatal infection was less common in Group 2 (1.8% vs. 5.7%; P < .001). The groups did not differ in the proportion of newborns treated for presumed infection (24.1% in Group 1 vs. 22.2% in Group 2).

Plentiful data confirm the superiority of preoperative administration

Endometritis is the most common postoperative complication associated with cesarean delivery. Wound infection is less common but more likely to lead to prolonged postoperative morbidity and extended hospitalization. Reducing both of these complications is a critical clinical objective.

Virtually without exception, every investigation has confirmed that prophylactic antibiotics reduce the frequency of postcesarean endometritis and, usually, wound infection as well. One dose of a given antibiotic is clearly as effective as multiple doses.

Classic animal investigations by Burke demonstrated that prophylaxis was most effective when antibiotics were present in tissue prior to the surgical incision.13 Nevertheless, early investigators in obstetrics argued that preoperative exposure to antibiotics increased the likelihood that the neonate would require an evaluation for sepsis and that delaying antibiotics until after cord clamping did not compromise the effectiveness of prophylaxis.14,15

 

 

Sullivan and colleagues were the first authors to successfully challenge this dictum.9 In a well-designed investigation, they demonstrated that preoperative administration of antibiotics significantly reduces the frequency of endometritis (RR, 0.22) but not wound infection, and does not increase the need for neonatal sepsis evaluation. Kaimel and coworkers later confirmed these findings,16 and this study by Owen and associates offers additional proof of the effectiveness and safety of preoperative antibiotic administration.

I offer only one addendum to the conclusions presented by Owen and colleagues. Two recent investigations from the University of Alabama conclusively demonstrate that, by extending the spectrum of antibiotic coverage by combining azithromycin and cefazolin, we can further reduce postcesarean endometritis and wound infection.11,17 Accordingly, at our center, we now administer both intravenous (IV) azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the rates of postcesarean endometritis and wound infection, and preoperative administration is superior to administration after cord clamping. Preoperative administration is also safe for the neonate.

Administer IV azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

Chlorhexidine solutions are superior to povidone-iodine for surgical-site antisepsis

Darouiche RO, Wall MJ, Itani KMF, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362(1):18–26.

This report is an excellent complement to the two studies discussed above, which focused on systemic antibiotic prophylaxis for the prevention of postcesarean infection. Here, Darouiche and colleagues conducted a randomized, prospective, unblinded, multi-center comparison of two skin preparations to prevent surgical-site infection:

  • 2% chlorhexidine gluconate and 70% isopropyl alcohol (409 patients)
  • 10% povidone-iodine solution (440 patients).

Participants underwent a variety of abdominal and nonabdominal (thoracic, gynecologic, and urologic) procedures. All patients received systemic antibiotic prophylaxis within 1 hour before the start of surgery.

The primary outcome measure was the occurrence of any surgical-site infection up to 30 days after surgery. This rate was lower among patients who received chlorhexidine-alcohol skin preparations than among those who received povidone-iodine (9.5% vs. 16.1%; P = .004).

Secondary endpoints were specific types of infection:

  • superficial incisional infection (skin and subcutaneous tissue): lower among patients receiving chlorhexidine-alcohol (4.2% vs. 8.6%; P = .008)
  • deep incisional infection (involving fascia and muscle): lower among patients receiving chlorhexidine-alcohol (1% vs. 3%; P = .05)
  • organ-space infection (any organ or space other than the body wall): no significant difference between women treated with chlorhexidine-alcohol and those treated with povidone-iodine.

Seventeen patients would need to be treated with chlorhexidine-alcohol to prevent one surgical-site infection.

Chlorhexidine has a solid track record

The 41% reduction in the rate of surgical-site infection with chlorhexidine-alcohol (RR, 0.59; 95% CI, 0.41–0.85) is consistent with a 49% reduction in the risk of vascular catheter-related bacteremia using the same formulation.18 The findings are also consistent with a recent report showing that chlorhexidine was more effective than iodine-containing solutions in reducing bacterial concentration in the operative field in women undergoing vaginal hysterectomy.19

Darouiche and coworkers suggest that chlorhexidine is more effective because it has a more rapid onset of action and greater and more persistent antibacterial activity despite exposure to body fluids. Quite appropriately, they indicate that the solution used in their study is flammable, but they observed no adverse effects in a large sample of patients undergoing a variety of procedures.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

I strongly recommend that chlorhexidine be used for all surgical skin preparation in obstetric and gynecologic patients. this intervention, along with consistent use of systemic antibiotic prophylaxis, should be highly effective in reducing the risk of superficial and deep abdominal wound infection.

Six recent articles stand out in the field of infectious disease:

  • an assessment of outcomes of seriously ill patients who were hospitalized early in the course of the H1N1 influenza epidemic. The authors highlight major differences in the epidemiology of this infection, compared with regular seasonal flu
  • an examination of outcomes of pregnant women who developed H1N1 influenza
  • an exploration of the use of blunt needles during cesarean delivery to prevent glove perforation
  • an evaluation of the utility of prophylactic antibiotics in ostensibly low-risk women undergoing scheduled cesarean delivery
  • a look at the timing of antibiotic prophylaxis for cesarean delivery
  • a comparison of skin preparation techniques in the prevention of surgical-site infection.

The focus on cesarean delivery in most of these studies seems particularly appropriate, now that this operation has become the most frequently performed major surgical procedure in US hospitals.

H1N1 virus hits hardest during pregnancy and chronic illness

Jain S, Kamimoto L, Bramley AM, et al, for 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935–1944.

This retrospective survey of patients hospitalized for at least 24 hours for treatment of influenza-like illness included 272 patients who were given a diagnosis of H1N1 influenza, based on real-time, reverse-transcriptase, polymerase chain reaction assay. Sixty-seven (25%) of these patients were admitted to an ICU, and 19 (7%) died. All of the patients who died had been treated in an ICU, and two thirds had an underlying medical condition. Three of the deaths involved pregnant women. None of the patients who died received antiviral therapy within 48 hours of the onset of symptoms. Those who died were also less likely to have been vaccinated against seasonal influenza in 2008–2009.

Details of the trial

The 272 patients included in this study sample represented 25% of the total number of patients hospitalized in the United States for treatment of influenza between April and mid-June 2009. They exhibited the following characteristics:

  • median age: 21 years
  • race and ethnicity: 30% were Hispanic, and 27% were non-Hispanic white
  • most common symptoms: fever and cough, although diarrhea or vomiting was reported in 39% of patients
  • underlying medical illness: present in 73% (198 patients), including 60% of children and 83% of adults. At least two underlying medical conditions were present in 32% of patients. Asthma was the most common comorbid condition
  • pregnancy: 18 patients were pregnant. Four of the pregnant patients also had asthma, and two had diabetes
  • obesity: 29% of adults were obese. Morbid obesity was present in 26%. More than 75% of obese and morbidly obese patients had at least one underlying medical illness
  • bloodwork at admission: 20% of patients were leukopenic; 37% were anemic; and 14% were thrombocytopenic
  • chest film: 40% of patients who underwent chest radiography had findings consistent with pneumonia. Findings included bilateral infiltrates in 66 patients, a unilobar infiltrate in 26, and multilobar infiltrates in two
  • antiviral therapy: 75% ultimately received antiviral drugs, with a median time from onset of illness to initiation of therapy of 3 days (range, 0–29 days). Only 39% received antiviral therapy within 48 hours of the onset of symptoms
  • antibiotic therapy: 79% of patients received antibiotics for presumed superimposed bacterial infection. The most commonly used antibiotics were ceftriaxone, azithromycin, vancomycin, and levofloxacin.

Study offers 4 useful lessons

The study by Jain and colleagues offers clinically applicable lessons:

  • it reinforces the point that children and young adults, including pregnant women, are at increased risk of serious morbidity and mortality
  • it demonstrates that most seriously affected patients have at least one underlying medical condition, such as asthma
  • it highlights the importance of pregnancy and morbid obesity as major conditions that contribute to serious complications from influenza. The 7% prevalence of pregnant patients is significantly higher than the 1% prevalence that would typically be expected with seasonal influenza. Similarly, the 26% prevalence of morbid obesity greatly exceeds the estimated 5% prevalence in the adult US population
  • it confirms the importance of treating patients early in the course of their illness with antiviral drugs such as oseltamivir. Notably, none of the patients who died received treatment within 48 hours of the onset of illness, when the drugs are most likely to be effective.

How to treat H1N1 influenza

The vast majority of strains of the 2009 H1N1 virus are susceptible to oseltamivir and zanamivir, but essentially all strains are resistant to amantadine and rimantadine.1 Therefore, all individuals who are hospitalized should be treated with one of two regimens:

  • oseltamivir, 75 mg orally, twice daily for at least 5 days
  • zanamivir, 10 mg by inhalation, twice daily for at least 5 days.
 

 

These same regimens should be used for outpatients who are at high risk of complications.

Ideally, antiviral treatment should be administered within 48 hours of the onset of symptoms, but do not withhold treatment even if more than 48 hours have elapsed since the onset of illness.2,3

Both oseltamivir and zanamivir are also effective for prevention of infection in susceptible patients who have been exposed to H1N1 influenza. The appropriate dosage of oseltamivir for prophylaxis is 75 mg orally once daily for 10 days. The corresponding dosage of zanamivir is 10 mg by inhalation once daily for 10 days.1

The most effective method of prophylaxis, of course, is vaccination with the new H1N1 vaccine.4 There are two forms of the vaccine—a live virus nasal vaccine and an inactivated vaccine for intramuscular administration. Pregnant women should receive only the inactivated vaccine.

The key reservoirs of all influenza A viruses are migrating waterfowl, pigs, and humans. The current H1N1 strain of virus contains eight unique RNA segments that are a mixture of components from avian, pig, and human influenza viruses.2 The pandemic resulting from this virus is unusual because the continent of origin was North America (Mexico) rather than Asia, the season of origin was spring rather than fall, and the patients at greatest risk of dying have been children and young adults rather than infants and the elderly.3

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Women who are pregnant or planning to become pregnant should be vaccinated against H1N1 influenza. Use the inactivated virus if a woman is already pregnant.

After exposure to H1N1 influenza, unvaccinated pregnant women and other patients at high risk of developing the virus should be given oseltamivir or zanamivir prophylactically, using the dosage and route of administration described above for prophylaxis.

Pregnant women and other high-risk patients who exhibit symptoms of H1N1 influenza should be given oseltamivir or zanamivir, using the dosage and route of administration described above for treatment, ideally within 48 hours of the onset of symptoms.

For pregnant and postpartum patients, base treatment of H1N1 flu on symptoms, not rapid tests

Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362(1):27–35.

Louie and coworkers describe the outcome of a statewide surveillance program by the California Department of Public Health. They reviewed the medical records of 94 pregnant women, eight women who were within the first 2 weeks postpartum, and 137 nonpregnant women of reproductive age who were hospitalized with confirmed 2009 H1N1 influenza between April 23 and August 11, 2009.

Eighteen pregnant women and four postpartum patients (22%) required intensive care, and 16 (73%) of these women had to be ventilated mechanically. Of the 18 pregnant women who required treatment in the ICU, 12 delivered in the hospital, and four underwent emergent cesarean delivery in the ICU.

Eight (8%) of the 102 pregnant and postpartum patients died. None of these eight women received antiviral therapy within 48 hours of the onset of symptoms. In fact, for pregnant and postpartum patients, a delay in administration of antiviral therapy beyond 48 hours after the onset of symptoms produced a 4.3 relative risk of death (95% confidence interval [CI], 1.4–13.7), compared with patients who were treated early in the course of their infection.

Details of the trial

The women in this trial had the following characteristics:

  • gestational age: five (5%) of the 94 pregnant women were in the first trimester, 35 (37%) were in the second trimester, and 54 (57%) were in the third trimester
  • underlying conditions were present in 34% of the pregnant and postpartum women and 60% of nonpregnant women. These conditions placed them at increased risk of complications from influenza. The most common underlying condition was asthma
  • antiviral therapy was administered to approximately 80% of both pregnant and nonpregnant women. However, only 50% of pregnant women and 34% of nonpregnant women received treatment within 48 hours of the onset of symptoms
  • antibiotic therapy was given to 45% of pregnant women and 58% of nonpregnant women for presumed secondary bacterial infection
  • false-negative test results: 153 women underwent rapid tests for influenza, 38% of which were falsely negative.

Treat pregnant patients expediently

This article is an excellent complement to the study by Jain and colleagues described on page 37. It strikingly illustrates the heightened risk of morbidity and mortality that pregnant women face when they develop H1N1 influenza. Louie and coworkers documented an influenza-specific mortality ratio (maternal deaths for every 100,000 live births) of 4.3. They also provide clear evidence of the perils of relying on rapid diagnostic tests and withholding antiviral treatment if the rapid test is negative. In their series, 38% of rapid tests were falsely negative. In pregnant women, when antiviral therapy was delayed more than 48 hours, the relative risk of death was 4.3, compared with patients who were treated within 48 hours of the onset of symptoms.

 

 

WHAT THIS EVIDENCE MEANS FOR PRACTICE

If there is a clinical suspicion of influenza in a pregnant or postpartum patient, treat her immediately with one of the antiviral regimens outlined on page 38—regardless of the outcome of the rapid test for influenza.

Blunt needles reduce needle sticks during cesarean delivery

Sullivan S, Williamson B, Wilson LK, Korde JE, Soper D. Blunt needles for reduction of needlestick injuries during cesarean delivery. Obstet Gynecol. 2009;114 (2 Pt 1):211–216.

Using glove perforation as a proxy for needlestick injuries, Sullivan and colleagues compared blunt needles with sharp needles during cesarean delivery. Ninety-seven women had all anatomic layers reapproximated using blunt needles, and 97 had them reapproximated using sharp needles. The overall glove perforation rate was 12.3%. For sharp needles, the perforation rate was 17.5%, and for blunt needles it was 7.2% (relative risk [RR], 0.66; 95% CI, 0.49–0.89). The key protective effect of the blunt needles was confined to the assistant surgeon (RR, 0.54; 95% CI, 0.41–0.71). The RR for glove perforation involving the primary surgeon was 0.8 (95% CI, 0.53–1.2).

Details of the trial

Glove type, number of gloves, needle size, and type and gauge of suture material were left to the discretion of the surgeon. Glove perforations were identified by filling the gloves with 1,000 mL of water and applying pressure to the palm and each finger. The secondary endpoint of the study was physician satisfaction with the needle. Primary and assistant surgeons reported comparable levels of dissatisfaction with blunt needles, compared with sharp needles (P < .001). However, 92% of primary surgeons and 93% of assistant surgeons rated the blunt needles as at least “acceptable” for use.

Needle stick has led to hepatitis B transmission

Earlier studies reported a rate of glove perforation of 20% to 26% during open abdominal procedures. In an investigation at our center, we noted glove perforation in 13% of cesarean deliveries.5 In this and another investigation, the frequency of perforation did not vary with the level of training of the surgeon or time of day of the procedure.5,6 The most common sites of perforation were the thumb, index finger, and middle finger of the non-dominant hand. The most common mechanism of injury was handling the needle with the operator’s gloved hand rather than with an instrument.

Double-gloving significantly reduces the risk of injury to the inner glove and, subsequently, to the surgeon’s skin. (Note: Double-gloving does not decrease tactile sensation or increase the risk of mishap.6)

The study by Sullivan and colleagues demonstrates that use of blunt needles offers an additional measure of protection against a penetrating injury to the surgeon’s bare skin. Although no surgeon has yet contracted HIV infection from a surgical needle, the transmission of hepatitis B via contaminated surgical needle has been well documented.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Prudence dictates that we use all proven measures to prevent intraoperative blood exposure. Use of blunt needles should be added to interventions such as double-gloving and use of a neutral zone in which to pass sharp objects.

Prophylactic antibiotics reduce postcesarean infection, even in low-risk women

Dinsmoor MJ, Gilbert S, Landon MB, et al, for Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. Obstet Gynecol. 2009;114(4):752–756.

Infection is the most common postoperative complication of cesarean delivery, now the most frequently performed major operation in America. The principal infection is endometritis, followed by wound infection and urinary tract infection. The frequency of wound infection is on the rise because of the steadily increasing prevalence of obesity in the obstetric population.

Dinsmoor and coworkers conducted this secondary analysis using data from an earlier observational study of 9,432 women who underwent cesarean delivery before the onset of labor. Of these women, 6,006 (64%) received antibiotic prophylaxis.

Women treated prophylactically had a significantly lower rate of endometritis (adjusted odds ratio [OR], 0.40; 95% CI, 0.28–0.59) and of wound infection (adjusted OR, 0.49; 95% CI, 0.28–0.86). The frequency of other infection-related complications was not significantly reduced (adjusted OR, 0.39; 95% CI, 0.13–1.12).

Overall, the size of the effect for endometritis was small; endometritis developed in 2.0% of women in the group that received prophylaxis and 2.6% of women in the group that did not. The size of the effect was even smaller for wound infection.

In this uncontrolled series, 113 patients had to be treated to prevent one case of endometritis or wound infection.

Details of the trial

The original observational study from which this analysis derives was performed by the Maternal-Fetal Medicine Units Network at 13 centers in 1999–2000. The choice of antibiotics and the timing of administration were left to the discretion of the attending physician.

 

 

Principal endpoints were the occurrence of postoperative endometritis and wound infection. Secondary endpoints were less common infection-related complications such as maternal sepsis, fascial dehiscence or evisceration, necrotizing fasciitis, pelvic abscess, and septic pelvic vein thrombophlebitis.

Of the women who were given prophylactic antibiotics, 88% received only a cephalosporin, 7% received only a broad-spectrum penicillin, and 6% received other regimens. Approximately 1% of patients received more than one antibiotic for prophylaxis.

Averting infection pays dividends

More than 90% of patients who have endometritis respond promptly to broad-spectrum antibiotic therapy. However, some women with postcesarean endometritis develop serious complications such as septic shock, septic pelvic vein thrombophlebitis, and pelvic abscess.

Treatment of wound infection is not so straightforward as treatment of endometritis. Wound infections may well require surgical intervention to drain an incisional abscess. They also necessitate a change in antibiotic therapy, and they are one of the two most important risk factors for fascial dehiscence and intestinal evisceration.

Multiple studies have confirmed that antibiotic prophylaxis significantly reduces the risk of endometritis and wound infection in women who undergo cesarean after the start of labor, with or without ruptured membranes.7,8 Recent publications have also demonstrated that prophylaxis before the start of surgery offers a greater protective effect than administration after the infant’s umbilical cord is clamped.9,10 Other investigations have demonstrated that broader-spectrum prophylaxis further improves outcomes in women undergoing cesarean delivery.11,12

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the frequency of postcesarean endometritis and wound infection, even in very low-risk patients. I strongly support the use of prophylactic antibiotics in all women undergoing cesarean delivery. I believe that the best available evidence supports the use of cefazolin (1 g) plus azithromycin (500 mg), administered intravenously before the start of surgery.9-12

Administer antibiotics before making the incision for greatest effectiveness

Owens SM, Brozanski BS, Meyn LA, Wisenfeld HC. Antimicrobial prophylaxis for cesarean delivery before skin incision. Obstet Gynecol. 2009;114(3):573–579.

In this retrospective investigation, Owens and colleagues compared antibiotic prophylaxis in two groups of women undergoing cesarean delivery:

  • 4,229 women who received antibiotics after the infant’s umbilical cord was clamped, from July 2002 to November 2004 (Group 1)
  • 4,781 women who received antibiotics before the skin was incised, from June 2005 to August 2007 (Group 2).

Both scheduled and unscheduled cesarean deliveries were included, as were women who received antibiotics intrapartum for group B streptococcus prophylaxis and treatment of chorioamnionitis. The most commonly used antibiotic was intravenous cefazolin (1 g).

After excluding women who received group B streptococcus prophylaxis or intrapartum treatment of chorioamnionitis, the authors demonstrated a nearly 50% reduction in the rate of endometritis among women who received antibiotics before surgery (OR, 0.54; 95% CI, 0.38–0.75). They also documented a 30% reduction in the rate of wound infection in these patients (OR, 0.72; 95% CI, 0.55–0.46).

Details of the trial

Principal outcome measures were the rates of maternal endometritis and wound infection and rates of proven and presumed neonatal infection. The mean age and racial distribution were similar in the two groups, but the percentage of patients treated on a resident teaching service was lower in Group 2 (14.9% vs. 18.9%; P < .001). The two groups did not differ in mean body mass index or in the percentage of patients who were in labor before surgery. Colonization with group B streptococcus was more common in Group 2 (24.4% vs. 22.2%; P = .5). However, chorioamnionitis was less prevalent in Group 2 (5.6% vs. 10.3%; P < .001).

The rates of culture-proven neonatal infection within the first 3 days of life (early-onset infection) were similar between groups (1.3% in Group 1 vs. 0.7% in Group 2). Culture-proven late-onset neonatal infection was less common in Group 2 (1.8% vs. 5.7%; P < .001). The groups did not differ in the proportion of newborns treated for presumed infection (24.1% in Group 1 vs. 22.2% in Group 2).

Plentiful data confirm the superiority of preoperative administration

Endometritis is the most common postoperative complication associated with cesarean delivery. Wound infection is less common but more likely to lead to prolonged postoperative morbidity and extended hospitalization. Reducing both of these complications is a critical clinical objective.

Virtually without exception, every investigation has confirmed that prophylactic antibiotics reduce the frequency of postcesarean endometritis and, usually, wound infection as well. One dose of a given antibiotic is clearly as effective as multiple doses.

Classic animal investigations by Burke demonstrated that prophylaxis was most effective when antibiotics were present in tissue prior to the surgical incision.13 Nevertheless, early investigators in obstetrics argued that preoperative exposure to antibiotics increased the likelihood that the neonate would require an evaluation for sepsis and that delaying antibiotics until after cord clamping did not compromise the effectiveness of prophylaxis.14,15

 

 

Sullivan and colleagues were the first authors to successfully challenge this dictum.9 In a well-designed investigation, they demonstrated that preoperative administration of antibiotics significantly reduces the frequency of endometritis (RR, 0.22) but not wound infection, and does not increase the need for neonatal sepsis evaluation. Kaimel and coworkers later confirmed these findings,16 and this study by Owen and associates offers additional proof of the effectiveness and safety of preoperative antibiotic administration.

I offer only one addendum to the conclusions presented by Owen and colleagues. Two recent investigations from the University of Alabama conclusively demonstrate that, by extending the spectrum of antibiotic coverage by combining azithromycin and cefazolin, we can further reduce postcesarean endometritis and wound infection.11,17 Accordingly, at our center, we now administer both intravenous (IV) azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

Antibiotic prophylaxis reduces the rates of postcesarean endometritis and wound infection, and preoperative administration is superior to administration after cord clamping. Preoperative administration is also safe for the neonate.

Administer IV azithromycin (500 mg over 1 hour) and IV cefazolin (1 g) approximately 30 to 60 minutes before the start of surgery.

Chlorhexidine solutions are superior to povidone-iodine for surgical-site antisepsis

Darouiche RO, Wall MJ, Itani KMF, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362(1):18–26.

This report is an excellent complement to the two studies discussed above, which focused on systemic antibiotic prophylaxis for the prevention of postcesarean infection. Here, Darouiche and colleagues conducted a randomized, prospective, unblinded, multi-center comparison of two skin preparations to prevent surgical-site infection:

  • 2% chlorhexidine gluconate and 70% isopropyl alcohol (409 patients)
  • 10% povidone-iodine solution (440 patients).

Participants underwent a variety of abdominal and nonabdominal (thoracic, gynecologic, and urologic) procedures. All patients received systemic antibiotic prophylaxis within 1 hour before the start of surgery.

The primary outcome measure was the occurrence of any surgical-site infection up to 30 days after surgery. This rate was lower among patients who received chlorhexidine-alcohol skin preparations than among those who received povidone-iodine (9.5% vs. 16.1%; P = .004).

Secondary endpoints were specific types of infection:

  • superficial incisional infection (skin and subcutaneous tissue): lower among patients receiving chlorhexidine-alcohol (4.2% vs. 8.6%; P = .008)
  • deep incisional infection (involving fascia and muscle): lower among patients receiving chlorhexidine-alcohol (1% vs. 3%; P = .05)
  • organ-space infection (any organ or space other than the body wall): no significant difference between women treated with chlorhexidine-alcohol and those treated with povidone-iodine.

Seventeen patients would need to be treated with chlorhexidine-alcohol to prevent one surgical-site infection.

Chlorhexidine has a solid track record

The 41% reduction in the rate of surgical-site infection with chlorhexidine-alcohol (RR, 0.59; 95% CI, 0.41–0.85) is consistent with a 49% reduction in the risk of vascular catheter-related bacteremia using the same formulation.18 The findings are also consistent with a recent report showing that chlorhexidine was more effective than iodine-containing solutions in reducing bacterial concentration in the operative field in women undergoing vaginal hysterectomy.19

Darouiche and coworkers suggest that chlorhexidine is more effective because it has a more rapid onset of action and greater and more persistent antibacterial activity despite exposure to body fluids. Quite appropriately, they indicate that the solution used in their study is flammable, but they observed no adverse effects in a large sample of patients undergoing a variety of procedures.

WHAT THIS EVIDENCE MEANS FOR PRACTICE

I strongly recommend that chlorhexidine be used for all surgical skin preparation in obstetric and gynecologic patients. this intervention, along with consistent use of systemic antibiotic prophylaxis, should be highly effective in reducing the risk of superficial and deep abdominal wound infection.

References

1. Antiviral drugs for influenza. The Medical Letter. 2009;51(1325):89-92.

2. Wenzel RP, Edmond MB. Preparing for 2009 H1N1 influenza. N Engl J Med. 2009;361(20):1991-1993.

3. Perez-Padilla R, Rosa-Zambori D, deLeon SP, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.

4. H1N1 vaccine for prevention of pandemic influenza. The Medical Letter. 2009;51(1322):77-78.

5. Chapman S, Duff P. Frequency of glove perforations and subsequent blood contact in association with selected obstetric surgical procedures. Am J Obstet Gynecol. 1993;168(5):1354-1357.

6. Lancaster C, Duff P. Single versus double-gloving for obstetric and gynecologic procedures. Am J Obstet Gynecol. 2007;196(5):e36-e37.

7. Smaill F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section. Cochrane Database of Systematic Reviews. 2002;(3):CD000933.-doi:10/1002/14651858.

8. Prophylactic antibiotics in labor and delivery. ACOG Practice Bulletin No. 47. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2003;102(4):875-882.

9. Sullivan SA, Smith T, Chang F, Hulsey T, Vandorsten JP, Soper D. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized controlled trial. Am J Obstet Gynecol. 2007;196(5):455.e1-e5.

10. Costantine MM, Rahman M, Ghulmiyah L, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol. 2008;199(3):301.e1-e6.

11. Tita ATN, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008;111(1):51-56.

12. Tita AT, Owen J, Stamm AM, Grimes A, Hauth JC, Andrews WW. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol. 2008;199(3):303.e1-e3.

13. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961;50:161-168.

14. Gordon HR, Phelps D, Blanchard K. Prophylactic cesarean section antibiotics: maternal and neonatal morbidity before and after cord clamping. Obstet Gynecol. 1979;53(2):151-156.

15. Cunningham FG, Leveno KJ, DePalma RT, Roark M, Rosenfeld CR. Perioperative antimicrobials for cesarean delivery: before or after cord clamping? Obstet Gynecol. 1983;62(2):151-154.

16. Kaimal AJ, Zlatnik MG, Chang YW, et al. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. Am J Obstet Gynecol. 2008;199(3):310.e1-e5.

17. Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systemic review. Obstet Gynecol. 2009;113(3):675-682.

18. Chaiyakunapruk N, Veerstra DI, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136(11):792-801.

19. Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005;192(2):422-425.

References

1. Antiviral drugs for influenza. The Medical Letter. 2009;51(1325):89-92.

2. Wenzel RP, Edmond MB. Preparing for 2009 H1N1 influenza. N Engl J Med. 2009;361(20):1991-1993.

3. Perez-Padilla R, Rosa-Zambori D, deLeon SP, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.

4. H1N1 vaccine for prevention of pandemic influenza. The Medical Letter. 2009;51(1322):77-78.

5. Chapman S, Duff P. Frequency of glove perforations and subsequent blood contact in association with selected obstetric surgical procedures. Am J Obstet Gynecol. 1993;168(5):1354-1357.

6. Lancaster C, Duff P. Single versus double-gloving for obstetric and gynecologic procedures. Am J Obstet Gynecol. 2007;196(5):e36-e37.

7. Smaill F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section. Cochrane Database of Systematic Reviews. 2002;(3):CD000933.-doi:10/1002/14651858.

8. Prophylactic antibiotics in labor and delivery. ACOG Practice Bulletin No. 47. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2003;102(4):875-882.

9. Sullivan SA, Smith T, Chang F, Hulsey T, Vandorsten JP, Soper D. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized controlled trial. Am J Obstet Gynecol. 2007;196(5):455.e1-e5.

10. Costantine MM, Rahman M, Ghulmiyah L, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol. 2008;199(3):301.e1-e6.

11. Tita ATN, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008;111(1):51-56.

12. Tita AT, Owen J, Stamm AM, Grimes A, Hauth JC, Andrews WW. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol. 2008;199(3):303.e1-e3.

13. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961;50:161-168.

14. Gordon HR, Phelps D, Blanchard K. Prophylactic cesarean section antibiotics: maternal and neonatal morbidity before and after cord clamping. Obstet Gynecol. 1979;53(2):151-156.

15. Cunningham FG, Leveno KJ, DePalma RT, Roark M, Rosenfeld CR. Perioperative antimicrobials for cesarean delivery: before or after cord clamping? Obstet Gynecol. 1983;62(2):151-154.

16. Kaimal AJ, Zlatnik MG, Chang YW, et al. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. Am J Obstet Gynecol. 2008;199(3):310.e1-e5.

17. Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systemic review. Obstet Gynecol. 2009;113(3):675-682.

18. Chaiyakunapruk N, Veerstra DI, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136(11):792-801.

19. Culligan PJ, Kubik K, Murphy M, Blackwell L, Snyder J. A randomized trial that compared povidone iodine and chlorhexidine as antiseptics for vaginal hysterectomy. Am J Obstet Gynecol. 2005;192(2):422-425.

Issue
OBG Management - 22(06)
Issue
OBG Management - 22(06)
Page Number
36-46
Page Number
36-46
Publications
Publications
Topics
Article Type
Display Headline
UPDATE: INFECTIOUS DISEASE
Display Headline
UPDATE: INFECTIOUS DISEASE
Sections
Article Source

PURLs Copyright

Inside the Article
Article PDF Media

Evaluating Correlation of Two Pain Scales in Spinal Procedures

Article Type
Changed
Display Headline
Evaluating Correlation of Two Pain Scales in Spinal Procedures

Article PDF
Author and Disclosure Information

David E. Fish, MD, MPH, Paul C. Lee, MD, Ashna Parti, MD, and Quynh Pham, MD

Dr. Fish is an associate clinical professor in the department of orthopaedics and Dr. Pham is an assistant professor, both at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Lee is a resident physician and Dr. Parti is a former resident physician and graduate, both of the UCLA/VA Greater Los Angeles Healthcare System (UCLA/VAGLAHS) multicampus physical medicine and rehabilitation residency training program. In addition, Dr. Pham is the program director of the UCLA/VAGLAHS pain medicine fellowship and physical medicine and rehabilitation residency training programs.

Issue
Federal Practitioner - 27(5)
Publications
Topics
Page Number
24
Legacy Keywords
pain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventionalpain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventional
Sections
Author and Disclosure Information

David E. Fish, MD, MPH, Paul C. Lee, MD, Ashna Parti, MD, and Quynh Pham, MD

Dr. Fish is an associate clinical professor in the department of orthopaedics and Dr. Pham is an assistant professor, both at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Lee is a resident physician and Dr. Parti is a former resident physician and graduate, both of the UCLA/VA Greater Los Angeles Healthcare System (UCLA/VAGLAHS) multicampus physical medicine and rehabilitation residency training program. In addition, Dr. Pham is the program director of the UCLA/VAGLAHS pain medicine fellowship and physical medicine and rehabilitation residency training programs.

Author and Disclosure Information

David E. Fish, MD, MPH, Paul C. Lee, MD, Ashna Parti, MD, and Quynh Pham, MD

Dr. Fish is an associate clinical professor in the department of orthopaedics and Dr. Pham is an assistant professor, both at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Dr. Lee is a resident physician and Dr. Parti is a former resident physician and graduate, both of the UCLA/VA Greater Los Angeles Healthcare System (UCLA/VAGLAHS) multicampus physical medicine and rehabilitation residency training program. In addition, Dr. Pham is the program director of the UCLA/VAGLAHS pain medicine fellowship and physical medicine and rehabilitation residency training programs.

Article PDF
Article PDF

Issue
Federal Practitioner - 27(5)
Issue
Federal Practitioner - 27(5)
Page Number
24
Page Number
24
Publications
Publications
Topics
Article Type
Display Headline
Evaluating Correlation of Two Pain Scales in Spinal Procedures
Display Headline
Evaluating Correlation of Two Pain Scales in Spinal Procedures
Legacy Keywords
pain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventionalpain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventional
Legacy Keywords
pain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventionalpain, pain scales, spine, spinal procedures, VA, visual analog scale, verbal numeric rating scale, VNRS, VAS, pain, pain management, intervention, interventional
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Barriers Preventing Older Veterans from Seeking Treatment for Erectile Dysfunction

Article Type
Changed
Display Headline
Barriers Preventing Older Veterans from Seeking Treatment for Erectile Dysfunction

Article PDF
Author and Disclosure Information

Shawkat Dhanani, MD, MPH, Nancy Harada, PT, PhD, and Takashi Makinodan, PhD

Dr. Dhanani is the chief of the geriatric evaluation and management unit and Dr. Makinodan is a health sciences officer, both at the VA Greater Los Angeles Healthcare System (VAGLAHS) Geriatric Research, Education, and Clinical Center (GRECC), Los Angeles, CA. Dr. Harada is an education specialist at the VAGLAHS. In addition, Dr. Dhanani is a professor of clinical medicine, Dr. Harada is an adjunct professor, and Dr. Makinodan is a professor of medicine, all at the University of California, Los Angeles.

Issue
Federal Practitioner - 27(5)
Publications
Page Number
16
Legacy Keywords
older veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyleolder veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyle
Sections
Author and Disclosure Information

Shawkat Dhanani, MD, MPH, Nancy Harada, PT, PhD, and Takashi Makinodan, PhD

Dr. Dhanani is the chief of the geriatric evaluation and management unit and Dr. Makinodan is a health sciences officer, both at the VA Greater Los Angeles Healthcare System (VAGLAHS) Geriatric Research, Education, and Clinical Center (GRECC), Los Angeles, CA. Dr. Harada is an education specialist at the VAGLAHS. In addition, Dr. Dhanani is a professor of clinical medicine, Dr. Harada is an adjunct professor, and Dr. Makinodan is a professor of medicine, all at the University of California, Los Angeles.

Author and Disclosure Information

Shawkat Dhanani, MD, MPH, Nancy Harada, PT, PhD, and Takashi Makinodan, PhD

Dr. Dhanani is the chief of the geriatric evaluation and management unit and Dr. Makinodan is a health sciences officer, both at the VA Greater Los Angeles Healthcare System (VAGLAHS) Geriatric Research, Education, and Clinical Center (GRECC), Los Angeles, CA. Dr. Harada is an education specialist at the VAGLAHS. In addition, Dr. Dhanani is a professor of clinical medicine, Dr. Harada is an adjunct professor, and Dr. Makinodan is a professor of medicine, all at the University of California, Los Angeles.

Article PDF
Article PDF

Issue
Federal Practitioner - 27(5)
Issue
Federal Practitioner - 27(5)
Page Number
16
Page Number
16
Publications
Publications
Article Type
Display Headline
Barriers Preventing Older Veterans from Seeking Treatment for Erectile Dysfunction
Display Headline
Barriers Preventing Older Veterans from Seeking Treatment for Erectile Dysfunction
Legacy Keywords
older veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyleolder veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyle
Legacy Keywords
older veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyleolder veterans, barriers, treatment, erectile dysfunction, ED, survey, sex, sexual, health beliefs, aging, lifestyle
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Patient Preferences of Chronic Kidney Disease Treatment

Article Type
Changed
Display Headline
Patient Preferences of Chronic Kidney Disease Treatment

Article PDF
Author and Disclosure Information

Issue
Federal Practitioner - 27(5)
Publications
Page Number
E1
Legacy Keywords
patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Issue
Federal Practitioner - 27(5)
Issue
Federal Practitioner - 27(5)
Page Number
E1
Page Number
E1
Publications
Publications
Article Type
Display Headline
Patient Preferences of Chronic Kidney Disease Treatment
Display Headline
Patient Preferences of Chronic Kidney Disease Treatment
Legacy Keywords
patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5
Legacy Keywords
patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5patient, preferences, chronic, kidney disease, treatment, CKD, dialysis, hemodialysis, transplant, renal replacement therapy, RRT, stage 5
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Grand Rounds: Man, 65, With Delayed Pain After Hand Injury

Article Type
Changed
Display Headline
Man, 65, With Delayed Pain After Hand Injury

A 65-year-old man presented to the emergency department (ED) with a two-week history of progressively severe pain in his right hand and difficulty moving his fingers. He reported that approximately two weeks earlier, while shoveling snow, he slipped and fell, landing on his right hand. Initially, he had no problems with his hand. He finished his shoveling and continued his normal daily activities.

Within two to three days he started to experience pain in his right hand, which grew progressively worse.

Because he did not have a primary care provider, the patient had a limited medical history. He reported having a mildly elevated prostate-specific antigen test years earlier. He underwent an appendectomy at age 15. He denied any other medical problems.

The patient was taking no medications and reported no known allergies to medications. He denied the use of tobacco, said he had one or two beers on an average day, and denied IV drug use. He was an artist and was married with one adult child. His family history was unremarkable with the exception of an alcoholic sister who died of cirrhosis at age 70.

During triage, vital signs were essentially normal: blood pressure, 142/74 mm Hg; heart rate, 78 beats/min; and respiratory rate, 20 breaths/min. The patient was afebrile at 37.2°C (98.9°F). Physical examination was remarkable for some edema and warmth of the right hand without any notable erythema. There was no evidence of any wound. Fingers all had good sensation; however, flexion of the index and long fingers elicited a significant increase in pain.

The remainder of the exam was unremarkable. The patient’s head was normocephalic and atraumatic. Pupils were equal, round, and reactive to light. Eyes were anicteric, and no rhinorrhea was evident. The neck was supple without palpable lymphadenopathy. Lungs were clear to auscultation bilaterally. No wheezes, rales, or rhonchi were appreciated. The heart had a regular rate and rhythm; no murmurs, rubs, or gallups were noted. The abdomen was soft and non-tender. The extremities, except as previously stated, were normal, with good pulses, sensation, and strength.

Initially, only radiographs of the right hand were ordered (see Figures 1 and 2). These demonstrated soft tissue swelling on the dorsum of the hand, and an area of hypodensity between the first and second metacarpals. There were no fractures, dislocations, or other bone or joint abnormalities.

After a review of the radiographs, it was clear that the patient’s diagnosis was not a simple answer of hand contusion or fracture; thus, the evaluation was expanded. Vital signs were repeated three hours after triage: blood pressure, 128/74 mm Hg; heart rate, 76 beats/min; and respiration, 20 breaths/min. The patient was now febrile at 37.6°C (99.7°F). Because of his fever and the anomaly on the patient’s hand radiograph, expansion of the evaluation continued.

Laboratory studies included a complete blood count: white blood cells (WBCs), 30,700/mcL (reference range,1 4,500 to 11,000/mcL); hemoglobin, 13.3 g/dL (13.8 to 17.2 g/dL for men); hematocrit, 40.0% (41% to 50% for men); platelets, 217,000/mcL (130 to 400 x 103/mcL). Initial chemistry panel results were normal except for serum glucose, 143 mg/dL (70 to 125 mg/dL).

Liver function test results were normal except for aspartate aminotransferase, 33 U/L (reference range,1 10 to 30 U/L) and albumin, 2.5 g/dL (3.5 to 5.0 g/dL). Once WBCs were found to exceed 30,000/mcL, the search for a cause was widened once more.

The continued studies included a chest radiograph with normal results, unremarkable CT of the abdomen and pelvis with IV contrast, blood cultures, and urinalysis. The urinalysis showed: blood, moderate; protein, trace; nitrites, positive; leukocytes, large; WBCs > 50/high-power field (reference range,1 5/high-power field or less); and numerous bacteria.

The final study performed in the ED evaluation of the patient was a CT of the right hand with IV contrast (see Figure 3). It demonstrated diffuse edema and a 9.0-mm area of low attenuation with some rim enhancement. The differential for these findings includes an abscess or a foreign body; the latter was deemed unlikely in light of the patient’s physical exam. In consideration of his elevated WBC count, the high number of WBCs in his urine, the fever, and the CT results, the patient was diagnosed with an abscess in his right hand that had been seeded, it was surmised, by an occult urosepsis after his fall.

Before the patient’s admission, a hand surgeon was consulted. The surgeon agreed with the diagnosis, and the patient was taken to the operating room (OR). He had been given piperacillin/tazobactam in the ED.

 

 

In the OR, the surgeon made a 3.0-cm incision, conducted an exploration, and identified a cavity that contained a small amount of purulence. He determined the lesion to be a resolving abscess. The wound was washed out, and the area was closed with a Penrose drain.

The patient was continued on the piperacillin/tazobactam. His blood culture was positive for gram-positive rods, and a low-grade fever persisted. An infectious disease specialist was consulted, and levofloxacin was added to the patient’s regimen.

After 24 hours of treatment, findings on urinalysis improved: blood, small; protein, trace; nitrites, negative; leukocytes, small; WBCs, 15 to 20/high-power field; and no bacteria. Over the next three days, the patient’s condition continued to improve. His hand drain was removed, and the pain and swelling subsided. He became afebrile, and his WBC count fell to 24,700/mcL. He was discharged to home with prescriptions for cephalexin and levofloxacin. Follow-up for postoperative care was arranged with the hand surgeon.

 

Discussion
Pyomyositis is defined as abscess formation deep within large striated muscles.1 Although this condition is uncommon, it is believed that an occult bacteremia can seed an area of damaged muscle (compared with healthy muscle, which ordinarily resists infection), allowing an abscess to form.1,2

Epidemiology
In a 2002 review involving 676 patients with primary pyomyositis, Bickels et al3 reported the condition in ages ranging from two months to 82 years (mean, 28.1 years). In a majority of cases, only a single muscle was involved; 112 patients (16.6%) were identified with multiple-site involvement. Only seven cases (0.1%) involved the hand.

In 452 cases (66.9%), a bacterial agent was identified. Among these, 350 (77%) had a positive culture for Staphylococcus aureus. Other isolates included Streptococcus pyogenes, Escherichia coli, Salmonella enteritidus, and Mycobacterium tuberculosis.1,3 It should be noted that community-­acquired methicillin-resistant S aureus (CA-MRSA) is being implicated with increasing frequency in cases of pyomyositis.4-6

Because pyomyositis is not a reportable disease and has not been studied in large clinical trials, its incidence is uncertain, and proposed risk factors have not all been confirmed2 (see Table2,7).

Pathophysiology
While the etiology of primary pyomyositis is unclear, it is believed to be caused by a combination of bacteremia (chronic or transient) and damaged muscle. In a 1960 study published in the Lancet, Smith and Vickers8 performed autopsies on 327 patients who had died of culture-positive septicemia. Only two patients were found to have a muscle abscess. At that time, the investigators concluded that both muscle injury and bacteremia would need to be present in order for an abscess to form. In animal studies, bacteremia (eg, S aureus) does not appear to lead to pyomyositis except in cases of muscle abnormality or trauma (eg, electric shock, pinching injury).9,10

When a history of trauma can be identified in patients with pyomyositis, the condition typically develops near the affected muscle, and the infection appears within days to weeks.3 In cases in which an antecedent infection is identified and hematogenous spread of the bacteria to the skeletal muscle occurs, this is termed secondary pyomyositis.11

Disease Progression
Pyomyositis generally progresses in three stages, beginning with inflammation and advancing to a focal abscess, then to a septic state.3 The first stage develops between seven and 21 days after the initial incident, is typically subacute, involves mild pain and swelling with a “woody” texture, and is occasionally associated with fevers.2

Diagnosis of pyomyositis is usually made during the second stage, 10 to 21 days after the initial incident; by that time, the pain has increased, and the fever is more pronounced. Third-stage infection usually involves fluctuance and sepsis.2

Although MRI is considered most useful in the diagnosis of pyomyositis, CT and ultrasound allow for percutaneous needle aspiration and drainage.3

Treatment
The correct treatment for pyomyositis depends upon the stage at which the disease is identified. During the first stage (before formation of an abscess), antibiotic treatment alone may be sufficient.1 Once an abscess has formed, an incision and drainage will be required, in conjunction with or followed by appropriate antibiotic therapy.

When pyomyositis is properly treated during the first or second stage, a full recovery is likely.2,3 By the third stage, surgical debridement is required. Additionally, osteomyelitis may develop in the adjacent bones, followed by muscle scarring, residual weakness, and functional impairment.2,3 Reported pyomyositis-associated mortality ranges between less than 1% and 4%.2,12

The Case Patient

The case presented here was of particular interest for two reasons. First, the patient had a traumatic injury that initially caused him no concern but worsened progressively over 14 days. Although this is not the typical presentation of a traumatic injury, the ED staff could very easily have performed a radiograph, made a diagnosis of traumatic hand injury, and discharged the patient.

 

 

Second, men in their 60s do not commonly have urinary tract infections.13 The patient was questioned frequently by several providers about sexual behaviors, medical problems, and urinary symptoms. Repeatedly, he denied all of these issues. While a urinalysis may be omitted in the evaluation of an otherwise healthy, asymptomatic patient, its results in this case were a key piece of data.

It should be noted that the patient thought it inappropriate to be asked for urine samples. He repeatedly said, “It’s my hand!”

Conclusion
Even in patients presenting with the most routine complaint, a careful evaluation can reveal unexpected, serious problems. This patient complained of pain in his hand some time after a fall and ultimately was treated for an occult urosepsis and hand abscess—pyomyositis, which rarely occurs in small muscles, such as those of the hand. Either condition, left untreated, could have led to serious morbidity or even mortality.

References

1. Beers MH, Berkow R, eds. Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories, 2006:1142-1143.

2. Crum-Cianflone NF. Bacterial, fungal, parasitic and viral myositis. Clin Microbiol Rev. 2008;21(3):473-494.

3. Bickels J, Ben-Sira L, Kessler A, Wientroub S. Current concepts review: primary pyomyositis. J Bone Joint Surg Am. 2002;84-A(12):2277-2286.

4. Lo BM, Fickenscher BA. Primary pyomyositis caused by ca-MRSA. Int J Emerg Med. 2008;1(4):331-332.

5. Ruiz ME, Yohannes S, Wladyka CG. Pyomyositis caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2005;352(14):1488–1489.

6. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43(8):953–960.

7. Ükinç K, Bayraktar M, Uzun O. A case of type 2 diabetes complicated with primary pyomyositis. Endocrinologist. 2009;19(3):129-130.

8. Smith IM, Vickers AB. Natural history of 338 treated and untreated patients with staphylococcal septicaemia (1936-1955). Lancet. 1960;1(7138):1318-1322.

9. Phoon E-S, Sebastin SJ, Tay S-C. Primary pyomyositis (bacterial myositis) of the pronator quadratus. J Hand Surg Eur Vol. 2009;34(4):549-551.

10. Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis. 1992; 15(4):668-677.

11. Sokolowski MJ, Koh JL. Pyomyositis of the shoulder girdle. Orthopedics. 2006;29(11):1030-1032.

12. Crum NF. Bacterial pyomyositis in the United States. Am J Med. 2004;117(6):420–428.

13. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 suppl 1A:5S-13S.

Author and Disclosure Information

 

David Jackson, MPAS, PA-C

Issue
Clinician Reviews - 20(5)
Publications
Topics
Page Number
14-16
Legacy Keywords
hand pain, injury, pyomyositishand pain, injury, pyomyositis
Sections
Author and Disclosure Information

 

David Jackson, MPAS, PA-C

Author and Disclosure Information

 

David Jackson, MPAS, PA-C

A 65-year-old man presented to the emergency department (ED) with a two-week history of progressively severe pain in his right hand and difficulty moving his fingers. He reported that approximately two weeks earlier, while shoveling snow, he slipped and fell, landing on his right hand. Initially, he had no problems with his hand. He finished his shoveling and continued his normal daily activities.

Within two to three days he started to experience pain in his right hand, which grew progressively worse.

Because he did not have a primary care provider, the patient had a limited medical history. He reported having a mildly elevated prostate-specific antigen test years earlier. He underwent an appendectomy at age 15. He denied any other medical problems.

The patient was taking no medications and reported no known allergies to medications. He denied the use of tobacco, said he had one or two beers on an average day, and denied IV drug use. He was an artist and was married with one adult child. His family history was unremarkable with the exception of an alcoholic sister who died of cirrhosis at age 70.

During triage, vital signs were essentially normal: blood pressure, 142/74 mm Hg; heart rate, 78 beats/min; and respiratory rate, 20 breaths/min. The patient was afebrile at 37.2°C (98.9°F). Physical examination was remarkable for some edema and warmth of the right hand without any notable erythema. There was no evidence of any wound. Fingers all had good sensation; however, flexion of the index and long fingers elicited a significant increase in pain.

The remainder of the exam was unremarkable. The patient’s head was normocephalic and atraumatic. Pupils were equal, round, and reactive to light. Eyes were anicteric, and no rhinorrhea was evident. The neck was supple without palpable lymphadenopathy. Lungs were clear to auscultation bilaterally. No wheezes, rales, or rhonchi were appreciated. The heart had a regular rate and rhythm; no murmurs, rubs, or gallups were noted. The abdomen was soft and non-tender. The extremities, except as previously stated, were normal, with good pulses, sensation, and strength.

Initially, only radiographs of the right hand were ordered (see Figures 1 and 2). These demonstrated soft tissue swelling on the dorsum of the hand, and an area of hypodensity between the first and second metacarpals. There were no fractures, dislocations, or other bone or joint abnormalities.

After a review of the radiographs, it was clear that the patient’s diagnosis was not a simple answer of hand contusion or fracture; thus, the evaluation was expanded. Vital signs were repeated three hours after triage: blood pressure, 128/74 mm Hg; heart rate, 76 beats/min; and respiration, 20 breaths/min. The patient was now febrile at 37.6°C (99.7°F). Because of his fever and the anomaly on the patient’s hand radiograph, expansion of the evaluation continued.

Laboratory studies included a complete blood count: white blood cells (WBCs), 30,700/mcL (reference range,1 4,500 to 11,000/mcL); hemoglobin, 13.3 g/dL (13.8 to 17.2 g/dL for men); hematocrit, 40.0% (41% to 50% for men); platelets, 217,000/mcL (130 to 400 x 103/mcL). Initial chemistry panel results were normal except for serum glucose, 143 mg/dL (70 to 125 mg/dL).

Liver function test results were normal except for aspartate aminotransferase, 33 U/L (reference range,1 10 to 30 U/L) and albumin, 2.5 g/dL (3.5 to 5.0 g/dL). Once WBCs were found to exceed 30,000/mcL, the search for a cause was widened once more.

The continued studies included a chest radiograph with normal results, unremarkable CT of the abdomen and pelvis with IV contrast, blood cultures, and urinalysis. The urinalysis showed: blood, moderate; protein, trace; nitrites, positive; leukocytes, large; WBCs > 50/high-power field (reference range,1 5/high-power field or less); and numerous bacteria.

The final study performed in the ED evaluation of the patient was a CT of the right hand with IV contrast (see Figure 3). It demonstrated diffuse edema and a 9.0-mm area of low attenuation with some rim enhancement. The differential for these findings includes an abscess or a foreign body; the latter was deemed unlikely in light of the patient’s physical exam. In consideration of his elevated WBC count, the high number of WBCs in his urine, the fever, and the CT results, the patient was diagnosed with an abscess in his right hand that had been seeded, it was surmised, by an occult urosepsis after his fall.

Before the patient’s admission, a hand surgeon was consulted. The surgeon agreed with the diagnosis, and the patient was taken to the operating room (OR). He had been given piperacillin/tazobactam in the ED.

 

 

In the OR, the surgeon made a 3.0-cm incision, conducted an exploration, and identified a cavity that contained a small amount of purulence. He determined the lesion to be a resolving abscess. The wound was washed out, and the area was closed with a Penrose drain.

The patient was continued on the piperacillin/tazobactam. His blood culture was positive for gram-positive rods, and a low-grade fever persisted. An infectious disease specialist was consulted, and levofloxacin was added to the patient’s regimen.

After 24 hours of treatment, findings on urinalysis improved: blood, small; protein, trace; nitrites, negative; leukocytes, small; WBCs, 15 to 20/high-power field; and no bacteria. Over the next three days, the patient’s condition continued to improve. His hand drain was removed, and the pain and swelling subsided. He became afebrile, and his WBC count fell to 24,700/mcL. He was discharged to home with prescriptions for cephalexin and levofloxacin. Follow-up for postoperative care was arranged with the hand surgeon.

 

Discussion
Pyomyositis is defined as abscess formation deep within large striated muscles.1 Although this condition is uncommon, it is believed that an occult bacteremia can seed an area of damaged muscle (compared with healthy muscle, which ordinarily resists infection), allowing an abscess to form.1,2

Epidemiology
In a 2002 review involving 676 patients with primary pyomyositis, Bickels et al3 reported the condition in ages ranging from two months to 82 years (mean, 28.1 years). In a majority of cases, only a single muscle was involved; 112 patients (16.6%) were identified with multiple-site involvement. Only seven cases (0.1%) involved the hand.

In 452 cases (66.9%), a bacterial agent was identified. Among these, 350 (77%) had a positive culture for Staphylococcus aureus. Other isolates included Streptococcus pyogenes, Escherichia coli, Salmonella enteritidus, and Mycobacterium tuberculosis.1,3 It should be noted that community-­acquired methicillin-resistant S aureus (CA-MRSA) is being implicated with increasing frequency in cases of pyomyositis.4-6

Because pyomyositis is not a reportable disease and has not been studied in large clinical trials, its incidence is uncertain, and proposed risk factors have not all been confirmed2 (see Table2,7).

Pathophysiology
While the etiology of primary pyomyositis is unclear, it is believed to be caused by a combination of bacteremia (chronic or transient) and damaged muscle. In a 1960 study published in the Lancet, Smith and Vickers8 performed autopsies on 327 patients who had died of culture-positive septicemia. Only two patients were found to have a muscle abscess. At that time, the investigators concluded that both muscle injury and bacteremia would need to be present in order for an abscess to form. In animal studies, bacteremia (eg, S aureus) does not appear to lead to pyomyositis except in cases of muscle abnormality or trauma (eg, electric shock, pinching injury).9,10

When a history of trauma can be identified in patients with pyomyositis, the condition typically develops near the affected muscle, and the infection appears within days to weeks.3 In cases in which an antecedent infection is identified and hematogenous spread of the bacteria to the skeletal muscle occurs, this is termed secondary pyomyositis.11

Disease Progression
Pyomyositis generally progresses in three stages, beginning with inflammation and advancing to a focal abscess, then to a septic state.3 The first stage develops between seven and 21 days after the initial incident, is typically subacute, involves mild pain and swelling with a “woody” texture, and is occasionally associated with fevers.2

Diagnosis of pyomyositis is usually made during the second stage, 10 to 21 days after the initial incident; by that time, the pain has increased, and the fever is more pronounced. Third-stage infection usually involves fluctuance and sepsis.2

Although MRI is considered most useful in the diagnosis of pyomyositis, CT and ultrasound allow for percutaneous needle aspiration and drainage.3

Treatment
The correct treatment for pyomyositis depends upon the stage at which the disease is identified. During the first stage (before formation of an abscess), antibiotic treatment alone may be sufficient.1 Once an abscess has formed, an incision and drainage will be required, in conjunction with or followed by appropriate antibiotic therapy.

When pyomyositis is properly treated during the first or second stage, a full recovery is likely.2,3 By the third stage, surgical debridement is required. Additionally, osteomyelitis may develop in the adjacent bones, followed by muscle scarring, residual weakness, and functional impairment.2,3 Reported pyomyositis-associated mortality ranges between less than 1% and 4%.2,12

The Case Patient

The case presented here was of particular interest for two reasons. First, the patient had a traumatic injury that initially caused him no concern but worsened progressively over 14 days. Although this is not the typical presentation of a traumatic injury, the ED staff could very easily have performed a radiograph, made a diagnosis of traumatic hand injury, and discharged the patient.

 

 

Second, men in their 60s do not commonly have urinary tract infections.13 The patient was questioned frequently by several providers about sexual behaviors, medical problems, and urinary symptoms. Repeatedly, he denied all of these issues. While a urinalysis may be omitted in the evaluation of an otherwise healthy, asymptomatic patient, its results in this case were a key piece of data.

It should be noted that the patient thought it inappropriate to be asked for urine samples. He repeatedly said, “It’s my hand!”

Conclusion
Even in patients presenting with the most routine complaint, a careful evaluation can reveal unexpected, serious problems. This patient complained of pain in his hand some time after a fall and ultimately was treated for an occult urosepsis and hand abscess—pyomyositis, which rarely occurs in small muscles, such as those of the hand. Either condition, left untreated, could have led to serious morbidity or even mortality.

A 65-year-old man presented to the emergency department (ED) with a two-week history of progressively severe pain in his right hand and difficulty moving his fingers. He reported that approximately two weeks earlier, while shoveling snow, he slipped and fell, landing on his right hand. Initially, he had no problems with his hand. He finished his shoveling and continued his normal daily activities.

Within two to three days he started to experience pain in his right hand, which grew progressively worse.

Because he did not have a primary care provider, the patient had a limited medical history. He reported having a mildly elevated prostate-specific antigen test years earlier. He underwent an appendectomy at age 15. He denied any other medical problems.

The patient was taking no medications and reported no known allergies to medications. He denied the use of tobacco, said he had one or two beers on an average day, and denied IV drug use. He was an artist and was married with one adult child. His family history was unremarkable with the exception of an alcoholic sister who died of cirrhosis at age 70.

During triage, vital signs were essentially normal: blood pressure, 142/74 mm Hg; heart rate, 78 beats/min; and respiratory rate, 20 breaths/min. The patient was afebrile at 37.2°C (98.9°F). Physical examination was remarkable for some edema and warmth of the right hand without any notable erythema. There was no evidence of any wound. Fingers all had good sensation; however, flexion of the index and long fingers elicited a significant increase in pain.

The remainder of the exam was unremarkable. The patient’s head was normocephalic and atraumatic. Pupils were equal, round, and reactive to light. Eyes were anicteric, and no rhinorrhea was evident. The neck was supple without palpable lymphadenopathy. Lungs were clear to auscultation bilaterally. No wheezes, rales, or rhonchi were appreciated. The heart had a regular rate and rhythm; no murmurs, rubs, or gallups were noted. The abdomen was soft and non-tender. The extremities, except as previously stated, were normal, with good pulses, sensation, and strength.

Initially, only radiographs of the right hand were ordered (see Figures 1 and 2). These demonstrated soft tissue swelling on the dorsum of the hand, and an area of hypodensity between the first and second metacarpals. There were no fractures, dislocations, or other bone or joint abnormalities.

After a review of the radiographs, it was clear that the patient’s diagnosis was not a simple answer of hand contusion or fracture; thus, the evaluation was expanded. Vital signs were repeated three hours after triage: blood pressure, 128/74 mm Hg; heart rate, 76 beats/min; and respiration, 20 breaths/min. The patient was now febrile at 37.6°C (99.7°F). Because of his fever and the anomaly on the patient’s hand radiograph, expansion of the evaluation continued.

Laboratory studies included a complete blood count: white blood cells (WBCs), 30,700/mcL (reference range,1 4,500 to 11,000/mcL); hemoglobin, 13.3 g/dL (13.8 to 17.2 g/dL for men); hematocrit, 40.0% (41% to 50% for men); platelets, 217,000/mcL (130 to 400 x 103/mcL). Initial chemistry panel results were normal except for serum glucose, 143 mg/dL (70 to 125 mg/dL).

Liver function test results were normal except for aspartate aminotransferase, 33 U/L (reference range,1 10 to 30 U/L) and albumin, 2.5 g/dL (3.5 to 5.0 g/dL). Once WBCs were found to exceed 30,000/mcL, the search for a cause was widened once more.

The continued studies included a chest radiograph with normal results, unremarkable CT of the abdomen and pelvis with IV contrast, blood cultures, and urinalysis. The urinalysis showed: blood, moderate; protein, trace; nitrites, positive; leukocytes, large; WBCs > 50/high-power field (reference range,1 5/high-power field or less); and numerous bacteria.

The final study performed in the ED evaluation of the patient was a CT of the right hand with IV contrast (see Figure 3). It demonstrated diffuse edema and a 9.0-mm area of low attenuation with some rim enhancement. The differential for these findings includes an abscess or a foreign body; the latter was deemed unlikely in light of the patient’s physical exam. In consideration of his elevated WBC count, the high number of WBCs in his urine, the fever, and the CT results, the patient was diagnosed with an abscess in his right hand that had been seeded, it was surmised, by an occult urosepsis after his fall.

Before the patient’s admission, a hand surgeon was consulted. The surgeon agreed with the diagnosis, and the patient was taken to the operating room (OR). He had been given piperacillin/tazobactam in the ED.

 

 

In the OR, the surgeon made a 3.0-cm incision, conducted an exploration, and identified a cavity that contained a small amount of purulence. He determined the lesion to be a resolving abscess. The wound was washed out, and the area was closed with a Penrose drain.

The patient was continued on the piperacillin/tazobactam. His blood culture was positive for gram-positive rods, and a low-grade fever persisted. An infectious disease specialist was consulted, and levofloxacin was added to the patient’s regimen.

After 24 hours of treatment, findings on urinalysis improved: blood, small; protein, trace; nitrites, negative; leukocytes, small; WBCs, 15 to 20/high-power field; and no bacteria. Over the next three days, the patient’s condition continued to improve. His hand drain was removed, and the pain and swelling subsided. He became afebrile, and his WBC count fell to 24,700/mcL. He was discharged to home with prescriptions for cephalexin and levofloxacin. Follow-up for postoperative care was arranged with the hand surgeon.

 

Discussion
Pyomyositis is defined as abscess formation deep within large striated muscles.1 Although this condition is uncommon, it is believed that an occult bacteremia can seed an area of damaged muscle (compared with healthy muscle, which ordinarily resists infection), allowing an abscess to form.1,2

Epidemiology
In a 2002 review involving 676 patients with primary pyomyositis, Bickels et al3 reported the condition in ages ranging from two months to 82 years (mean, 28.1 years). In a majority of cases, only a single muscle was involved; 112 patients (16.6%) were identified with multiple-site involvement. Only seven cases (0.1%) involved the hand.

In 452 cases (66.9%), a bacterial agent was identified. Among these, 350 (77%) had a positive culture for Staphylococcus aureus. Other isolates included Streptococcus pyogenes, Escherichia coli, Salmonella enteritidus, and Mycobacterium tuberculosis.1,3 It should be noted that community-­acquired methicillin-resistant S aureus (CA-MRSA) is being implicated with increasing frequency in cases of pyomyositis.4-6

Because pyomyositis is not a reportable disease and has not been studied in large clinical trials, its incidence is uncertain, and proposed risk factors have not all been confirmed2 (see Table2,7).

Pathophysiology
While the etiology of primary pyomyositis is unclear, it is believed to be caused by a combination of bacteremia (chronic or transient) and damaged muscle. In a 1960 study published in the Lancet, Smith and Vickers8 performed autopsies on 327 patients who had died of culture-positive septicemia. Only two patients were found to have a muscle abscess. At that time, the investigators concluded that both muscle injury and bacteremia would need to be present in order for an abscess to form. In animal studies, bacteremia (eg, S aureus) does not appear to lead to pyomyositis except in cases of muscle abnormality or trauma (eg, electric shock, pinching injury).9,10

When a history of trauma can be identified in patients with pyomyositis, the condition typically develops near the affected muscle, and the infection appears within days to weeks.3 In cases in which an antecedent infection is identified and hematogenous spread of the bacteria to the skeletal muscle occurs, this is termed secondary pyomyositis.11

Disease Progression
Pyomyositis generally progresses in three stages, beginning with inflammation and advancing to a focal abscess, then to a septic state.3 The first stage develops between seven and 21 days after the initial incident, is typically subacute, involves mild pain and swelling with a “woody” texture, and is occasionally associated with fevers.2

Diagnosis of pyomyositis is usually made during the second stage, 10 to 21 days after the initial incident; by that time, the pain has increased, and the fever is more pronounced. Third-stage infection usually involves fluctuance and sepsis.2

Although MRI is considered most useful in the diagnosis of pyomyositis, CT and ultrasound allow for percutaneous needle aspiration and drainage.3

Treatment
The correct treatment for pyomyositis depends upon the stage at which the disease is identified. During the first stage (before formation of an abscess), antibiotic treatment alone may be sufficient.1 Once an abscess has formed, an incision and drainage will be required, in conjunction with or followed by appropriate antibiotic therapy.

When pyomyositis is properly treated during the first or second stage, a full recovery is likely.2,3 By the third stage, surgical debridement is required. Additionally, osteomyelitis may develop in the adjacent bones, followed by muscle scarring, residual weakness, and functional impairment.2,3 Reported pyomyositis-associated mortality ranges between less than 1% and 4%.2,12

The Case Patient

The case presented here was of particular interest for two reasons. First, the patient had a traumatic injury that initially caused him no concern but worsened progressively over 14 days. Although this is not the typical presentation of a traumatic injury, the ED staff could very easily have performed a radiograph, made a diagnosis of traumatic hand injury, and discharged the patient.

 

 

Second, men in their 60s do not commonly have urinary tract infections.13 The patient was questioned frequently by several providers about sexual behaviors, medical problems, and urinary symptoms. Repeatedly, he denied all of these issues. While a urinalysis may be omitted in the evaluation of an otherwise healthy, asymptomatic patient, its results in this case were a key piece of data.

It should be noted that the patient thought it inappropriate to be asked for urine samples. He repeatedly said, “It’s my hand!”

Conclusion
Even in patients presenting with the most routine complaint, a careful evaluation can reveal unexpected, serious problems. This patient complained of pain in his hand some time after a fall and ultimately was treated for an occult urosepsis and hand abscess—pyomyositis, which rarely occurs in small muscles, such as those of the hand. Either condition, left untreated, could have led to serious morbidity or even mortality.

References

1. Beers MH, Berkow R, eds. Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories, 2006:1142-1143.

2. Crum-Cianflone NF. Bacterial, fungal, parasitic and viral myositis. Clin Microbiol Rev. 2008;21(3):473-494.

3. Bickels J, Ben-Sira L, Kessler A, Wientroub S. Current concepts review: primary pyomyositis. J Bone Joint Surg Am. 2002;84-A(12):2277-2286.

4. Lo BM, Fickenscher BA. Primary pyomyositis caused by ca-MRSA. Int J Emerg Med. 2008;1(4):331-332.

5. Ruiz ME, Yohannes S, Wladyka CG. Pyomyositis caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2005;352(14):1488–1489.

6. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43(8):953–960.

7. Ükinç K, Bayraktar M, Uzun O. A case of type 2 diabetes complicated with primary pyomyositis. Endocrinologist. 2009;19(3):129-130.

8. Smith IM, Vickers AB. Natural history of 338 treated and untreated patients with staphylococcal septicaemia (1936-1955). Lancet. 1960;1(7138):1318-1322.

9. Phoon E-S, Sebastin SJ, Tay S-C. Primary pyomyositis (bacterial myositis) of the pronator quadratus. J Hand Surg Eur Vol. 2009;34(4):549-551.

10. Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis. 1992; 15(4):668-677.

11. Sokolowski MJ, Koh JL. Pyomyositis of the shoulder girdle. Orthopedics. 2006;29(11):1030-1032.

12. Crum NF. Bacterial pyomyositis in the United States. Am J Med. 2004;117(6):420–428.

13. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 suppl 1A:5S-13S.

References

1. Beers MH, Berkow R, eds. Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories, 2006:1142-1143.

2. Crum-Cianflone NF. Bacterial, fungal, parasitic and viral myositis. Clin Microbiol Rev. 2008;21(3):473-494.

3. Bickels J, Ben-Sira L, Kessler A, Wientroub S. Current concepts review: primary pyomyositis. J Bone Joint Surg Am. 2002;84-A(12):2277-2286.

4. Lo BM, Fickenscher BA. Primary pyomyositis caused by ca-MRSA. Int J Emerg Med. 2008;1(4):331-332.

5. Ruiz ME, Yohannes S, Wladyka CG. Pyomyositis caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2005;352(14):1488–1489.

6. Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43(8):953–960.

7. Ükinç K, Bayraktar M, Uzun O. A case of type 2 diabetes complicated with primary pyomyositis. Endocrinologist. 2009;19(3):129-130.

8. Smith IM, Vickers AB. Natural history of 338 treated and untreated patients with staphylococcal septicaemia (1936-1955). Lancet. 1960;1(7138):1318-1322.

9. Phoon E-S, Sebastin SJ, Tay S-C. Primary pyomyositis (bacterial myositis) of the pronator quadratus. J Hand Surg Eur Vol. 2009;34(4):549-551.

10. Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis. 1992; 15(4):668-677.

11. Sokolowski MJ, Koh JL. Pyomyositis of the shoulder girdle. Orthopedics. 2006;29(11):1030-1032.

12. Crum NF. Bacterial pyomyositis in the United States. Am J Med. 2004;117(6):420–428.

13. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 suppl 1A:5S-13S.

Issue
Clinician Reviews - 20(5)
Issue
Clinician Reviews - 20(5)
Page Number
14-16
Page Number
14-16
Publications
Publications
Topics
Article Type
Display Headline
Man, 65, With Delayed Pain After Hand Injury
Display Headline
Man, 65, With Delayed Pain After Hand Injury
Legacy Keywords
hand pain, injury, pyomyositishand pain, injury, pyomyositis
Legacy Keywords
hand pain, injury, pyomyositishand pain, injury, pyomyositis
Sections
Disallow All Ads
Alternative CME